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SUMMARY AND AIMS
The World Health Organisation defines osteoporosis as a bone mineral density which 
is more than 2.5 standard deviations below the young adult mean. This deficit of bone 
tissue is widespread in older members of the population and is a cause of increased 
fragility and fracture risk. Injuries resulting from this insufficiency are a major cause 
of pain, deformity, lost independence and morbidity and represents a considerable 
drain on Health Service resources.
It is accepted that osteoporosis is caused by a focal imbalance in the bone remodelling 
cycle and, in the early stages of the post menopausal variant, the pattern of loss is 
consistent with an increase in bone resorption. More recent evidence however 
suggests that bone loss in the later stages of the disease and in all other forms of 
osteoporosis, is due to a reduction in bone formation at the tissue level. This reduction 
appears to be due to a decline in the number of osteoblasts, the cause of which is 
currently unknown.
In the post-natal organism, osteoblasts are derived from clonogenic precursors (CFU- 
F) associated with the soft fibrous tissue of the marrow stroma. Studies have shown 
that a sub-set of the CFU-F population is capable of giving rise to all of the cell 
lineages necessary for bone formation and the recreation of the haematopoietic micro 
environment.
One mechanism that has been postulated to account for the decline in osteoblast 
number is that an age related reduction in the number of CFU-F causes a reduction in 
the number of potential osteogenic precursors. Identifying the causes of the osteoblast 
deficit in osteoporosis ultimately depends on an improved understanding of the 
factors that induce the promotion of uncommitted cells to committed osteoprogenitors 
and regulate the regulate the size of the CFU-F population.
As these hypotheses are largely based on studies in animals or animal bone cells, the 
purpose of this project is to investigate these possibilities using cells derived from 
adult human bone marrow. The specific aims are to identify factors that promote the 
proliferation and osteogenic differentiation of human bone marrow CFU-F
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The importance of improving the current understanding and management of 
osteoporosis becomes obvious when the extent and effects of this disorder are 
considered.
Osteoporosis may be defined as one of a widespread heterogeneous group of 
disorders characterised by decreased bone mass and abnormal bone remodelling 1. 
The condition causes an increase in the risk of fractures to the femoral neck, vertebrae 
and radius causing loss of independence, deformity and pain. Complications arising 
from these injuries are also the cause of great morbidity, 15% of older women 
sustaining femoral neck fractures, die within 6 months from resultant complications^.
Economically, the 60, 000 hip fractures, 50, 000 wrist and 40, 000 vertebal fractures 
currently attributable to osteoporosis are costing the health service an estimated £750 
million per annum3.
Similar to many pathological conditions, osteoporosis is a multifactorial disease and 
is categorised either as Primary (with sub-types 1 and 2) or Secondary. Table 1.1 
below, summarises the important differences between them.
Table 1.1 
Primary Osteoporosis
Type_______Affects___________ Cause_______ Bone Loss_____ Fractures
1 Post-menopausal Oestrogen deficiency Mainly Trabecular Vertebral + Radial
women
2  Men + Women Ageing Cortical Hip
+Trabecular
_____________________ Secondary Osteoporosis, Some Causes.______________
Alcohol, Smoking, Cushing’s Syndrome, Hypogonadism, Menstrual dysfunction, Hyperthyroidism, 
Anorexia nervosa, Excessive exercise, Pregnancy, Rheumatoid Arthritis, Myeloma, Chronic liver 
disease, Malabsorption, Systemic Mastocytosis
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Common to all types of osteoporosis is a focal imbalance between the activity of 
osteoclasts and osteoblasts during the remodelling cycle that results in a net loss of 
bone. In normal adults 25% of cancellous bone is resorbed and replaced every year, 
compared with only 3% of cortical bone^. Therefore in osteoporosis, it can be 
expected that cancellous bone will endure erosion to a greater extent.
1.1.1: Bone Metabolism: Influencing Factors.
The focal imbalance in osteoporosis can be caused by:
Increased resorption, formation normal 
Normal resorption, formation reduced
Increased resorption and formation but the former more than the latter 
Decreased resorption and formation but the latter more than the former 
Increased resorption may be caused by:
(i) Increased rates of osteoclastic activity 
(at the expense of osteoblastic activity)
(ii) Increased frequency of activation of absorption sites 
Reduced formation may be caused by:
(i) Altered function of osteoblasts
(ii) Increased depth of resorption cavities with loss of template
(iii) Impaired recruitment of osteoblasts.
As osteoporosis is associated with local changes in trabecular bone mass and 
structure, any of the above situations could result from a disturbance of the local 
microenvironment or in the levels of systemic hormones known influence the 





(c) Severely osteoporotic vertebrae 
Note the loss of trabecular continuity 
due to resorptive perforations.
Figure 1.1: Scanning Electron Micrographs of Trabecular Bone






Taken from; Eriksen, E.F. Bone Histomorphometry. 
New York, Raven Press: 1994
1.2: Bone.
Bony, or osseous tissue, is a specialised connective tissue that combines the strength 
of cast iron with the lightness of wood. Functionally, bone serves three main 
purposes.
(i) Mechanical; providing support and muscle attachment sites required for 
locomotion.
(ii) Protective; safeguarding vital organs such as brain, spinal cord and bone marrow 
from external trauma.
(iii) Storage; serving as a site for reserves of calcium and phosphate.
Additionally, the bone marrow is the site of haematopoesis in the post-natal organism 
and source of connective tissue stem cells. It is important to emphasize that bone is 
not a dry, lifeless, brittle structure, but that, on the contrary, it is a living, dynamic, 
productive tissue that is continually formed, resorbed and reformed.
Like other sub-types of connective tissue, bone is composed of cells embedded in a 
matrix of osteoid and fibres**. Bone rigidity is provided by the deposition of 
inorganic salts such as calcium phosphate and calcium carbonate in the osteoid. Once 
deposited these substances undergo phase transitions and develop into a form of 
hydroxyapatite which may be ionised when required to provide calcium and 
phosphate to satisfy transient bodily needs. The organisation of collagenous fibres in 
the matrix contributes towards bone strength and flexibility.
1.2.1: Bone Cells.
Four types of bone cell comprise the cellular component of bone and they have the 
ability to modify their function in response to bodily demands.
Osteoblasts are metabolically active cells found on the developing surfaces of bone 
and are the principal cells of bone formation. Osteoblasts arise from osteoprogenitor 
cells of mesenchymal origin (pre-osteoblasts) and are highly differentiated and non­
dividing cells 9.
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Histologically, the mature osteoblast is cuboidal in shape and possesses a polarised 
arrangement of o r g a n e l l e s  10 (fig. 1.2). Extensive amounts of rough endoplasmic 
reticulum (RER) are found clustered in the cytoplasm nearest the bone surface and at 
the opposing end of the cell lies the nucleus containing 1-3 nucleoli. Sandwiched 
between the nucleus and the RER is found a prominent Golgi apparatus. The deep 
basophilic staining associated with osteoblasts is related to the abundance of glycogen 
vesicles which fuel the metabolic needs of the cell. Osteoblasts also stain positively 
for the enzyme alkaline phosphatase (discussed below) which is localised to the 
plasma membrane.
The developmental progress from stem cell to the osteoblast phenotype is marked by 
several stages of differentiation. Current knowledge of the nature of these 
commitment steps is however, still relatively poor. Using morphological and 
histochemical criteria coupled to analysis of proliferation, four maturational stages 
have been identified in bone in situ - pre-osteoblast, osteoblast, osteocyte and bone 
lining c e ll^ . By these criteria, osteoblasts are recognizable as post-proliferative and 
cuboidal, strongly alkaline phosphatase positive cells in contact with bone matrix at 
sites of osteogenesis.
The pre-osteoblast is recognised as the immediate precursor of the osteoblast and is 
identified by its position, one to two cell layers behind the osteoblast front. Although 
pre-osteoblasts resemble osteoblasts histologically and ultrastructurally and also 
express for alkaline phosphatase, they have not acquired many of the other 
differentiated features of fully mature cells 12. Figure 1.3 shows a widely accepted 
view of the phenotypic stages associated with osteoblast differentiation. The 
principle function of the osteoblast is to synthesise bone matrix facilitating the 
production of new bone. Synthesis of new bone occurs in 4 sequential steps:
(i) Synthesis and intracellular processing of type I collagen and non-collagenous 
proteins.
(ii) Secretion and extracellular processing of the collagen and non-collagenous 
proteins.
(iii) Formation of microfibrils, fibrils and fibres from the collagen.
(iv) Maturation of the collagen matrix (osteoid) with subsequent nucleation and 
growth of hydroxy apatite crystals (mineralisation) 10.
20








Figure 1.3: Steps in Osteoblast Lineage Implying Recognizable Stages of 
Differentiation (Adapted from Aubin H).
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The mechanism of mineralisation is not yet fully understood but it is accepted that it 
is an extracellular event. In woven bone, cartilage, dentin and cementum the onset of 
mineralisation is frequently associated with the appearance of vesicular structures 
termed matrix vesicles. These are typically located some distance from the cells 
where mineralisation is to occur. They measure about lOOnm in diameter and are 
formed by the pinching off of plasma membrane from the cells producing the 
mineralised tissue (e.g.. osteoblasts). Matrix vesicles contain alkaline phosphatase 
and other enzymes that are considered to load the membrane of the vesicle, then the 
vesicle itself with calcium and phosphate. It is thought that on rupturing, the vesicle 
causes a local increase in mineral concentrations sufficient to initiate mineralisation 9. 
In lamellar bone the mechanism of mineralisation appears to be different. 
Mineralisation is initiated in the gap between overlapping collagen molecules (fig. 1. 
7) where there are few matrix vesicles and appears to be initiated by components of 
the collagen itself or non-collagenous proteins at this site ^ . It is known that the 
mineral in mature calcified bone consists of carbonated hydroxyapatite crystals 
approximately 1.5 nm X 30 nm and it is thought that these needle shaped structures 
align with the collagen fibrils.
Throughout the osteogenic process, osteoblasts are influenced by both systemic 
hormones and, local agents in the form of growth factors, cytokines and other short 
lived diffusable mediators e.g. prostaglandins and nitric oxide. Interestingly, it has 
been postulated that the paracrine regulation of bone formation is dependant on, at 
least in part, the release and activation of matrix bound factors deposited during 
previous rounds of bone formation.
As bone formation proceeds, a subset of osteoblasts differentiate further into a 
relatively inactive flattened cell known as a bone lining cell, while others become 
entombed in a mineralised matrix of their own making. When the osteoblast becomes 
totally encased, access to nutrients becomes severely restricted resulting in a 
concomitant reduction in metabolic activity. At this stage the enclosed osteoblast 
becomes known as an osteocyte.
Bone Lining Cells are osteoblasts which have undergone an extra stage of 
differentiation and are found on the endosteal surface of most bones. A major 
function of these cells is thought to involve the establishment of an ion barrier around 
bone tissue, thus regulating the influx and outflow of calcium and phosphate to and
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from the m atrix^. Recent work has suggested that these cells may also have the 
ability to dedifferentiate, ^  providing a ready source of osteoblasts at times of crises, 
e.g.. during fracture repa ir^ . Bone lining cells may also exert an influence on bone 
remodelling by regulating osteoclast access to bone surfaces.
Osteocvtes are found in lacunae, small cavities in the calcified matrix and, are the 
most abundant cell type in bone. It is estimated that osteocytes exceed osteoblast 
numbers by approximately 10 fold 17.
Histologically, osteocytes appear as cells with a large nucleus to cytoplasmic ratio,
resulting in a thin rim of cytoplasm. Long cytoplasmic extensions give the cell a
stellate appearance allowing nutritional access and intercommunication between
adjacent osteocytes within the matrix. Osteoblasts and bone lining cells on the bone
surface are also accessible via this network (fig. 1. 4). The cytoplasmic extensions
are routed through the surrounding matrix via minute channels known as canaliculi 9.
Transmission electron microscopical (TEM) examination of the cell reveals a paucity
of RER and diminished Golgi complex, reflecting a reduced level of cellular function 
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Osteocytes are derived from the same multipotential mesenchymal stem cells as the 
osteoblast and represent an alternative state of terminal differentiation of the 
osteoblast lineage. The mechanism by which osteoblasts differentiate into osteocytes 
is not well understood. During bone formation, a proportion of osteoblasts lining the 
surface of bone are left behind and become incorporated into the newly laid osteoid 
matrix while other osteoblasts move on. It is thought that 10-20% of osteoblasts 
become embedded in a mineralised matrix of their own m a k in g  19.
It is thought the osteocyte performs several roles. One is the maintenance of bone 
matrix, utilising a limited capacity to synthesise and resorb matrix. Death of an 
osteocyte results in the resorption of the matrix by osteoclastic activity followed by 
the repair or remodelling of the tissue by osteoblasts^. Evidence suggests that 
osteocytes are also the mechanosensory cells of bone and play a central role in its 




Figure 1.4: Schematic Representation of Relationship 
between Bone Cells and Matrix.
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bone results in a very small deformation, or strain on bone tissue. This deformation of 
the bone matrix then results in a flow of interstitial fluid through the osteocyte 
canalicular network from regions of high strain to low strain. Electrical potentials 
induced by the flow, along with the fluid shear stress are then thought to modulate the 
production of signalling factors such as IGF-1 and prostaglandins by the 
osteocytes 21. It has also been suggested that osteocytes released from fracture sites 
may de-differentiate to osteoblasts, providing an urgently required source of bone 
forming cells at the trauma site
Osteoclasts are giant multinucleated cells found at sites of bone turnover and are 
responsible for bone resorption22-24 These cells are of haemopoietic origin, derived 
from the CFU-M monocyte-macrophage fam ily^ (fig. 1. 5).
Progenitor cells are recruited from the haemopoietic tissues such as bone marrow and 
splenic tissues and transported to bone via the circulating bloodstream 26.
Osteoclasts are distinguished by their large size, acidophilic staining characteristics, 
foamy cytoplasms and, by their multinuclearity, commonly containing between 10-20 
nuclei per cell. Other ultrastructural characteristics of the osteoclast include large 
numbers of lysosomes, numerous and pleomorphic mitochondria and extensive Golgi 
complexes located in the perinuclear a r e a  27.
The portion of the cell directly in contact with the bone can be divided into two parts: 
a ruffled border containing numerous finger-like invaginations of the plasma 
membrane and a clear zone, an organelle free area rich in actin-like filaments. The 
clear zone demarcates the limit of bone area being resorbed (fig. 1. 6).
Osteoclasts resorb bone by the release of lysosomal hydrolases into the extracellular 
space at the ruffled border. Hydrolytic enzymes including collaganase, cause the 
digestion of the extracellular organic component of the extracellular matrix. 
Concomitantly, decalcification (i.e.. the dissolution of calcium salts) occurs through 
the secretion of organic acids such as carbonic acid, by the membranes of the ruffled 
border. Because acid hydrolases favour a low pH, the osteoclast maintains an acidic 
environment in the extracellular space between the bone and the osteoclast. It is 
thought that the ruffled border also provides a large surface area for the absorption of 
the degraded bone m atrix^’ 18
26
Figure 1.5: Proposed Lineage of the Osteoclast 10.
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Figure 1.6: Schematic Diagram of an Osteoclast Showing Positions 









The composition of bone matrix varies with bone type, site, infiltration of cartilage, 
marrow and blood vessels and therefore a complete and universal description is 
impossible28. Generally the bone matrix can be described as having an inorganic and 
an organic component at a dry weight ratio of 65:35 respectively.
The inorganic component comprises of calcium phosphate (85%) calcium carbonate 
(10%) with significant quantities of bicarbonate and hydroxyl ions. Magnesium, 
sodium, potassium, fluorite, citrate and sulphate are minor constituents. The calcium 
and phosphate form hydroxyapatite crystals of 1.5 x 30 nm dimensions. These bind to 
collagen in a parallel formation and are surrounded by osteoid 18.
The organic component is mostly (approx. 90%) type I collagen, a fibrillar protein 
produced by osteoblasts. The type I collagen molecule is the basic building block of 
the bone matrix system. The molecule is a triple-helical supercoil containing two 
identical _1(I) chains and a structurally similar but genetically different _2(I) chain. In 
the matrix, individual collagen molecules are packed end to end with a short space 
between them. The molecules are packed laterally in a one quarter stagger array 
offsetting each molecule from its neighbour by one-fourth of its lengthlO (fig. 1.7).
This 3-dimensional arrangement constitutes the fibre structure found in the bone 
matrix. Minute amounts of type III, V and II, X may also be found but these are 
thought to be contaminants derived from blood vessels and cartilage respectively.
Non-collagenous proteins (NCP) present in the matrix comprise 10-15% of the total 
bone protein content and can be categorised into four general groups. 10.
(i) Cell attachment proteins
(ii) Proteoglycans
(iii) y-Carboxylated (gla) proteins
(iv) Growth related proteins
These classifications are often overlapping and by no means exhaustive as most of the 
roles for individual NCPs are currently undefined.
29
Figure 1.7: Type 1 collagen is secreted as a propeptide, but the N telopeptide and the 
C Telopeptide are rapidly cleaved by specific proteases (vertical arrows).
(adapted from Rossert, J., de Crombrugghe, B., Type I Collagen: Structure, Synthesis 
and Regulation. In; Principles in Bone Biology. Academic Press, San Diego 1996).
Figure 1.7: (a) Schematic Representation of a Type 1 Procollagen Molecule 
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Cell attachment proteins. To facilitate bone cell interactions with the extracellular 
environment, bone cells synthesise four proteins that affect cell attachment: 
Fibronectin, thrombospondin, osteopontin and bone sialoprotein. Cell attachment is 
important for the co-ordination of many cellular functions including cell 
proliferation, differentiation and migration 29. Osteopontin and bone sialoprotein are 
also known to anchor osteoclasts at resorption sites 30,31
Proteoglycans are macromolecules that contain acidic polysaccharide side chains
(glycosaminoglycans) attached to a central core protein. In bone two types of
glycosaminoglycan are found: chondroitin sulphate and heparin sulphate 10. Heparin
sulfate proteoglycan is membrane associated and is thought to facilitate the
interaction of osteoblasts with extracellular macromolecules such as fibronectin and
thrombospondin as well as heparin binding growth factors 32. The role of chondroitin
sulfate is not yet understood but it is thought to play a role in preserving the integrity
of the environment immediately outside the cell membrane. Most of the
glycosaminoglycans of bone are attached to two small (40 kDa) proteoglycan core
proteins, PG-I (biglycan) and PG-II (decorin), whose precise functions are not known
but are assumed to be important for the integrity of most connective tissue matrices 
33.
y-Carboxylated fglal proteins. Two structurally related, vitamin K-dependant, 
y-carboxylated (gla) proteins are found among the NCPs: osteocalcin (bone gla- 
protein) and matrix gla-protein ( M G P ) 3 4 .  Osteocalcin is bone specific and acts as a 
signal in the bone turnover cascade In knockout mice, bone mass was increased due 
to an increase in the rate of cortical and trabecular bone formation suggesting 
osteocalcin acts to inhibit bone formation in vivo 35. The precise function of matrix 
gla-protein, which is found in cartilage and bone, is unknown 10.
Growth related proteins. The most abundant NCP produced by bone cells is the 
growth related protein osteonectin. This protein has high affinity for binding ionic 
calcium, 10 hydroxy apatite, collagen and thrombospondin 36 jt is also thought to 
participate in osteoblast growth and proliferation as well as matrix mineralisation.
Transforming Growth Factor ft (TGFpl. TGF(3 is a 390 amino acid (AA) polypeptide 
secreted by osteoblasts which belongs to a superfamily of multifunctional structurally 
related cytokines 37. The importance of this molecule is revealed when it is realised 
that:
31
(i) TGFp is highly conserved; identical in human, monkey, bovine, porcine and avian 
forms.
(ii) Many cell types produce TGFp .(eg. Fibroblasts, mesothelial cells, transformed 
cells and osteoblasts)
(iii) Almost every cell type studied to date has receptors for T G Fp.
(iv) TGFp has significant effects on almost every cell possessing receptors for it.
The TGFp family includes three mammalian isoforms, TGFpl,~P2, and-p3. Three 
types of receptor exist.; high affinity types I+II; and low affinity type 111,38 ^  js 
thought that most cells types possess these receptors39. Human TGFp receptors bind 
all three isoforms; type I binds; p i  = P 2 > P 3 ;  type II binds; p i > P2 > p3and type 
III; p i = P2 = P3 .
Receptor signalling. Receptors type I+II are serine/threonine specific protein kinases 
and signal transduction, upon ligand binding, requires the formation of a heteromeric 
complex of both (fig. 1.8). The type IE receptors are thought not to transduce signals 
but function to concentrate TGFp on the cell surface, presenting it to the Type I + II
receptors 38.
Subsequent signal transduction has not been fully e lu c id a ted ^ . It is thought that the 
activation of the serine/threonine protein kinase domain of the type II subunit 
stimulates phospholipase C (PLC) breakdown of membrane inositol phospholipid; 
phosphatidylinositol 4,5 bisphosphate -> inositol 1,4,5 trisphosphate + diacyl glycerol 
(PIP2 -> IP3 + DAG). IP3 stimulates the release of RER stored calcium, which along 
with DAG, activates a protein kinase C (PKC) induced calcium influx38.
Recent work has implicated a number of potential downstream targets of the 
TGFP superfamily pathways. The most convincing data in support of a critical role in 
this process are those obtained for the Smad related proteins (human homologue of 
mothers against decapentaplegic (MAD) gene from drosophila)40-45
In mammalian cells, the induction of BMP signalling pathways causes the 
phosphorylation of Smadl through some unknown pathway and, the subsequent 
translocation of the protein from the cytoplasm to the nucleous46 ,47  Although this 
suggests the possibility that Smads act as transcriptional regulators, it is not clear
32
whether the Smads bind directly to DNA or act via some intermediary DNA-binding 
proteins. ( The PI second messenger system, overview fig. 1.18).
Biological Effects of TGFp. TGFp exerts a wide ranging autocrine and paracine 
regulatory influence on many cell types39. Studies have shown it to both stimulate 
and inhibit proliferation, modulate differentiation, angiogenesis, cell cycle 
progression, bone formation, and extracellular matrix p ro d u c tio n 4 8 -5 2 } 
mechanisms important in tissue development, remodelling and repair. The diversity 
of effects modulated by TGFP is dependant on phenotype and/or stage of
differentiation^.
In vitro, TGFp has been shown to both inhibit and stimulate osteoblast cell 
proliferation and increase markers of osteoblast differentiation such as tissue non­
specific alkaline phosphatase (A P ), Type I collagen and osteonectin^.
In vivo, TGFp has been shown to regulate osteoblast differentiation and modulate the 
coupling of bone formation to bone r e s o r p t i o n ^ .  Treatment with TGFp causes 
increased periosteal bone formation adjacent to sites of local a p p l i c a t i o n ^ .  Fracture 
repair is enhanced by both the local^S,56 anc[ system ic57-59 application of TGFp.
33
Figure 1.8: Schematic view of TGFB Receptors38
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Fibroblast Growth Factors Fibroblast Growth Factors (FGFs) were first characterised 
in the mid 1970s as a mitogen of cultured f i b r o b l a s t s ^ .  The FGF family currently 
has 9 members and their structural similarity suggest a common ancestral g e n e ^ l .  
The biological effects of the FGFs are modulated via 3 discrete biochemical entities.
(i) Low affinity trans-membrane binding proteins
(ii) Heparin sulphate oligosaccharaides.
(iii) High affinity transmembrane tyrosine kinase receptors. 60.
To date, four tyrosine kinase receptors have been identified (FGFr 1-4)38, where 
ligand binding activates intracellular signal transduction pathways. Activation 
requires receptor oligomerization, mediated by the association of heparin with the 
FGF ligand and, of the ligand with the receptor. The function of the low affinity 
transmembrane binding protein is unclear although suggestions indicating a role in 
the cellular uptake of FGF have been made^O.
The four tyrosine kinase receptor proteins each contain an extracellular region 
containing three immunoglobulin (Ig) like domains, a transmembrane segment and a 
split cytoplasmic tyrosine kinase r e g i o n 62 ( f i g .  1.9). The receptors have amino acid 
homology of 55-72% with differing ligand affinities and tissue distribution.
Splice variants of the FGF 1-3 receptor genes give rise to multiple receptor forms 
which exhibit structural differences,- some of the receptor variants for example lack 
the first immunoglobulin domain while others exhibit differences in the carboxy 
terminal part of the 3rd immunoglobulin domain or, contain deletions within the intra 
or extracellular r e g i o n s ^ .
FGF receptors and their variants all bind more than one type of FGF with high 
affinity. Similarly, any given FGF can bind to more than one receptor with high 
affinity.
Receptor Signalling. Ligand binding to the FGFr stimulates dimerization and 
phosphorylation. Receptors then bind to PLCY and stimulate the PI second messenger 
system. (Fig. 1.18).
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Biological Effects of FGF. FGFs and their receptors play a crucial role in normal and 
abnormal bone development. This has been demonstrated recently with the discovery 
of unique mutations in FGFr 1-3 which give rise to a variety of skeletal disorders 62. 
For example, a point mutation in the FGFr-3 gene causes achondroplasia, the most 
common form of d w a r f is m  64. Similar defects in the FGFr-2 and FGFr-1 genes cause 
Crouzon and Pfeiffer Syndromes respectively, both examples of craniosyntosis 
disorders 62.
In vitro, FG F-2 has been shown to be a potent mitogen for bone marrow stromal cells 
and to increase the capacity of these cells to produce a bone-like tissue65-67 
In vivo, treatment with FG F-2 stimulates osteoblast grow th^  and increases bone 
form ation69-71 enhancing fracture repair 72.
Bone Morphogenetic Proteins (BMPs). BMPs are dimeric growth factors which 
comprise part of the TGFP superfamily of multifunctional structurally related 
cytokines. Nine BMPs have so far been identified, all having relative degrees of 
sequence homology and exhibiting a wide range of biological functions in a diversity 
of tissue types73. Common to most BMPs is the ability to induce osteogenesis in 
bone and at ectopic sites74-76.
Although much less information exists regarding the BMP receptor species than is 
known for other members of the TGFP family, it is known that the BMP 
osteoinductive mechanism is modulated via two distinct receptors of the 
serine/threonine kinase family77(fig. 1.10). Type I receptors are subdivided into 
subtypes ALK-2, ALK-3, and ALK-6 while Type II receptors are further divided into 
T-ALK, ActRII and ActRIIb subtypes. The Type I+II receptors have been shown to 
bind only BMPs 2, 4, and 7, receptors for other BMPs are not apparent at the present 
time.
Unlike receptors for TGFp, BMP Type I and II receptors can bind ligands in the 
absence of each other, although formation of a Type I-II receptor complex may be a 
requirement for downstream signalling^ . The precise downstream signalling 
pathway, initiated by BMP ligand binding, is currently not well understood^.
37
Figure 1.10: Schematic diagram of BMP receptors.
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Biological Effects of BMPs. In vivo , implantation of BMPs-2, 4, 5, 6 , 7 or 9 into a 
wide range of tissues induces bone and cartilage formation75,80-82 Interestingly, all 
the heterodimeric BMPs tested to date have demonstrated a higher specific activity 
than their homodimer components^.
In vitro, BMPs have demonstrated an ability to act as both positive and negative 
regulators of proliferation and differentiation in a number of cell types83, Their most 
striking characteristic is their ability to induce an osteogenic phenotype in 
undifferentiated mesenchymal cells79,84
Taken as a whole, current knowledge strongly suggests that the primary target of 
BMPs is an early mesenchymal cell which when challenged with BMPs differentiates 
into osteoblast-like and chondroblast-like cells.
Insulin-like Growth Factors (TGF-I. IGF-ID. The IGFs are anabolic peptides 
structurally and functionally related to insulin and are the most abundant of the 
growth factors located within the bone microenvironment*^. An important function 
of the IGFs is to act as paracine/autocrine regulators of bone formation*^.
IGFs exist in vivo complexed to larger proteins termed IGF binding proteins 
(IGFBPs). Six IGFBPs are known to exist, IGFBP 1-6, and these function to 
prolong the half-life of the small IGF molecule and, because most IGFBPs prevent 
IGF binding to IGF receptors, they also act as regulators of IGF activity 87.
IGFs exert their effects via two specific membrane spanning receptors****’*^. The 
Type I is a tyrosine kinase receptor which is structurally related to the insulin 
receptor with a preferential binding affinity: IGF-I > IGF-II > Insulin. Ligand binding 
to the Type I receptor initiates the PI second messenger system. The Type II receptor 
binds IGF-H and lysosomal enzymes with high affinity but does not bind in s u l in  90, it 
is also lacking in tyrosine kinase activity. It is thought the Type II receptor is involved 
in receptor mediated internalisation and lysosomal enzyme sorting and trafficking91.
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Biological Effects of IGFs. As with other bone derived growth factors, IGFs not only 
act as acute paracine/autocrine regulators, but also become incorporated into bone 
matrix and may be released later during resorption. IGFs modulate bone formation in 
a number of ways; by stimulating proliferation and differentiation of osteoblast 
precursors 92; by modulating the effects of systemic hormones on bone formation 92; 
and acting as a paracrine regulator of osteoclast resorption^. IGF infusion increases 
bone formation in normal and osteopenic rats94 and significantly improves bone 
repair in calvarial defects 95. jn vitro IGFs increase deoxyribonucleic acid (DNA) 
synthesis and replication of cells of the osteoblast lineage and stimulate differentiated 
function of the mature osteoblast86,96
Platelet Derived Growth Factor (PDGF). PDGF is a polypeptide growth factor that 
was initially isolated from human platelets and subsequently found in other cell 
systems. Since PDGF is present in platelets and expressed in other cell types it is 
considered to act as both a systemic and local regulator of cell metabolism^.
PDGF is composed of two polypeptide chains that may be combined in a homo- or 
heterodimeric form. The chains are products of the related genes PDGF A and PDGF 
B, so PDGF can exist as either PDGF A A, PDGF BB homodimers or PDGF AB
heterodimer 98.
Two PDGF receptors are recognised, a  and p, (fig. 1.11) which have a 44% amino 
acid sequence homology. The receptors are members of the tyrosine kinase family, 
containing a catalytic tyrosine kinase domain in the intracellular region of the 
receptor and a immunoglobulin-like domains in the extracellular portion 99. PDGF A 
chains bind primarily to the a  receptor whereas PDGF B chains bind to either the a  
or P receptor 100. PDGF binding induces dimerization and activates downstream 
signal transduction pathways which are not well established. It is thought that the 
PKC, -phospholipase C-y , -PI- 3 kinase,- calcium flux pathway is involved 101.
PDGF AA, BB and AB have similar biological actions in skeletal and non-skeletal 
cells but with differing potencies. The efficacy of the different isoforms is ranked 
thus: BB > AB > AA102. The primary effect of PDGF on bone is mitogenic, 
stimulating bone cell replication in both intact calvaria and isolated osteoblasts 102. 
Exposure to PDGF does not enhance the differentiation of the osteoblast and it is 
thought that its role may be to increase the pool of osteoprogenitor cells which will 
eventually express the osteoblast phenotype 97. in addition to its effects on bone cell
40
proliferation, PDGF BB and AB increase bone resorption by a mechanism which is 
currently unknown 103#
Considered as a whole, current knowledge suggests that it is unlikely that PDGF A or 
B, play a role in the maintenance of bone mass, however the actions of PDGF on 
bone cell replication suggest a possible role in fracture healing and repair.
41
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Table 1.2: Summary of Bone Cell Derived Growth Factors and their Effects on
Osteoblasts 105̂
Factor kDa Concentration Proliferation Differentiation
in matrix (ng/g)
IGF2 7.5 1500 |  |
TGFp 50 450 |  |
IGF1 7.7 100 A |
PDGF 35 60 A ^
FGF 33 60 A ^
BMP-2 30-35 Total, 1-2 A |
BMP-3 30-40 A ^
BMP-4 30-35 A j
BMP-5 30-35 A 9
BMP-6 30-35 A 9
BMP-7 30-35 A j
BMP-8 30-35 |  |
BMP-9 30-35 A i
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1.2.3: Organisation of Bone.
The cells and matrix of bone tissue are organised to maximise the relationship 
between structure and function. Bone which forms initially in development (i.e.. 
primitive bone) is termed woven bone and this is transformed through remodelling 
processes into lamellar bone.
Bone may be classified in a number of ways and can be characterised as cortical 
(compact) or trabecular (cancellous or spongy). Cortical and trabecular bone are 
constituted of the same cells and matrix elements but there are structural and 
functional differences 106 Trabecular bone like that found inside the epiphysis, or 
head of long bones is always surrounded by cortical bone. Trabecular bone has large, 
open spaces surrounded by thin, anastomosing plates of bone. Cortical bone is much 
denser than trabecular.
In cortical bone of the human the smallest organisational unit is the osteon, or 
Haversian system (fig. 1.12). This structure consists of a central Haversian canal 
surrounded by concentric lamellae (of mineralised matrix) in which are found 
osteocytes residing in cavities known as lacunae. The function of the Haversian canal 
is to provide a cavity through which arteries, veins and nerves may pass. 107.
Osteocytes intercommunicate by utilising their long cytoplasmic extensions via 
canaliculi, small communicating channels found between the lacunae. Running at 
right angles to the Haversian canals are found Volkmann's canals, these provide extra 
pathways, allowing a greater mass of bone to be reached by the neuro-vascular 
system. The mass of dense compact bone is formed by parallel arrangements of 
osteons and this arrangement encloses the alternative type of bone mentioned above, 
the cancellous bone 9.
Similar to compact bone, cancellous bone possesses lacunae housing osteocytes, but 
unlike compact bone, the matrix is not arranged into osteons. Cancellous bone is 
comprised of a lattice of matrix, giving the appearance of it being sponge-like to the 
naked eye. This arrangement of matrix allows an efficient distribution of applied 
loads.
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Three distinct surfaces, or envelopes, of bone are recognised 108 the periosteum, the 
endosteum and the Haversian surface. Except for the articular surfaces, the external 
surface of the bone is surrounded by the periosteum, a two layered membrane with an 
outer fibrous collagenous layer and an inner osteogenic layer. In this inner layer are 
found osteogenic cells and osteoblasts, both cell types of fundamental importance in 
bone remodelling. The Haversian surfaces are found lining the Haversian canals and 
the remaining bone substance of the cancellous trabeculum is enclosed in endosteum. 
The periosteum is attached to bone via Sharpeys fibres,- collagenous bundles of 
fibrocartilage trapped in the calcified bone matrix 108
Bone formation. To understand this complex process it is important to distinguish 
between the development of bone as an organ and the histogenesis of bone tissue. The 
development of bone is traditionally classified as either endochondral or 
intramembranous ossification^.
Endochondral ossification. In this process, proliferation and aggregation of 
mesenchymal cells occur at the site of impending bone formation. The mesenchymal 
cells differentiate into chondroblasts which produce a hyaline cartilage matrix 
acquiring the general shape and appearance of the specific bone to be formed. 
Ossification occurs when the perichondrium (a cartilage equivalent to bone 
periosteum) ceases to give rise to chondrocytes and instead produces osteoblasts. 
Because of the change of function the perichondrium is now called the periosteum. 
As a result of the changes a thin layer of bone is formed around the cartilage 
template. With the establishment of the periosteal bone, chondrocytes in the cartilage 
become hypertrophic resulting in the compression of the surrounding cartilage. The 
compressed cartilage forms irregular plates between the hypertrophic cells which at 
this stage express alkaline phosphatase causing the concomitant calcification of the 
cartilage matrix9.
The calcification of the matrix inhibits the diffusion of nutrients resulting in the death 
of chondrocytes and the breakdown of the matrix. In the case of a long bone this 
cavity eventually becomes the marrow space. At this stage, blood vessels invade and 
vascularise the cavity providing an access to the primitive cells which eventually give 
rise to the marrow.
Intramembranous ossification. In this mechanism bone is formed through the 
differentiation of mesenchymal cells into osteoblasts. This process is initiated when 
condensations of mesenchymal cells within mesenchymal tissue congregate at sites
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destined to become bone. (The condensations of cells in the tissue is the “membrane” 
referred to in the term “intramembranous ossification”). As the process continues, the 
newly organised tissue becomes more vascularised, this initiates the osteogenic 
differentiation of the mesenchymal cells. The newly formed osteoblasts secrete 
osteoid which in time becomes calcified, with a proportion of the osteoblasts 
becoming trapped in the osteoid as described above. As osteoblasts are non-dividing 
cells they are replaced by the proliferation of primitive cells from the “membrane” 
which eventually give rise to osteoprogenitor cell^.
1.3: Bone Remodelling.
The bone remodelling cycle is a complex process co-ordinated by an elaborate 
interplay between systemic hormones, local bone derived factors and cytokines.
This process is achieved through the actions of basic multicellular units (BMUs), 
teams of bone resorbing osteoclasts and bone building osteoblasts 109 BMUs 
engineer the resorption of old bone by osteoclasts and the subsequent deposition of 
new bone by osteoblasts (fig. 1.13). This allows the skeleton to respond to 
microdamage by continuous modification through renewal and repair, whilst 
maintaining its anatomical and structural integrity. The role of the skeleton as a 
mineral reservoir is also facilitated by the remodelling process. The normal sequence 
of bone remodelling is outlined below: 4
(i) Quiescence: Inactive bone surface covered in lining cells
(ii) Recruitment: Mononuclear osteoclast precursors are recruited locally
(iii) Activation: Bone lining cells respond to bone resorbing hormones by contracting 
to allow osteoclast access and release of proteolytic enzymes (collaganase, 
plasminogen activators)
(iv) Resorption: As osteoclasts differentiate, migrate and fuse with the bone surface. 
Resorption occurs as osteoclasts release mineral dissolving hydrogen ions and matrix 
dissolving lysosomal enzymes. Osteoblast stimulating growth factors are released and 
activated as a by product of this process. When resorption is complete, the reversal 
phase occurs. Macrophages-like cells appear on the surface and complete resorption 
and/or, produce factors which aid osteoblastic bone formation. However, their exact 
role is uncertain.
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(v) Formation: New bone replacement depends on four main factors and a departure 
from these conditions may lead to a pathological imbalance in the bone resorption / 
formation cy c led  The factors are:
(i) Presence of unresorbed bone to act as a template
(ii) Release of local growth factors from cells and matrix which provide the signal for 
osteoblast activation.
(iii) Ability of osteoblast precursors to proliferate and differentiate
(iv) Capacity of the osteoblast to produce normal matrix.
48





Quiescent bone surface 
covered by lining cells
Osteoclasts on bone surface 
resorbing old bone
Osteoblasts appear at 
resorption site
Osteoid becomes mineralised Osteoblasts fill resorbed 
cavity with osteoid
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The systemic hormones that are involved with the regulation of remodelling can be 









An overview of these hormones (below) will place emphasis on those having 
particular relevance to this study.
1.3.1: Parathyroid Hormone (PTH). Calcitonin and 1. 25-Dihvdroxvvitamin D3 .
PTH is an 84 amino acid polypeptide secreted by the parathyroid gland, calcitonin a 
32 amino acid polypeptide secreted by the thyroid gland and 1, 25-dihydroxy vitamin 
D3 (calcitriol), a steroid hormone synthesised primarily in the kidney. The principal 
function of these three hormones is to act in concert to regulate serum calcium and 
phosphate levels10 (fig. 1.14). Physiologically, their target organs are the kidney, the 
intestine and bone. Regulation is achieved by four mechanisms:
(i) PTH stimulates calcium reabsorption and phosphate excretion from the glomerular 
filtrate. Phosphate is normally reabsorbed from the glomerular filtrate in both the 
proximal and distal tubules, PTH acting on these sites, inhibits phosphate absorption. 
PTH treatment also decreases calcium reabsorbtion in the proximal tubule but this 
loss is compensated by increased absorption in the distal tubule, causing a net gain in 
serum calcium levels HO.
(ii) PTH stimulation of the renal conversion of 25 (OH)2 D3 ->1, 25(OH)2 D3 thereby 
increasing the absorption of calcium and phosphate across the gut 111.
(iii) PTH stimulation of calcium and phosphate release from bone 10. PTH actions on 
bone are somewhat paradoxical and poorly understood. In its familiar physiological 
role, chronic administration of PTH stimulates osteoclastogenesis and hence bone 
resorption 10,112,113
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Figure 1.14: Schematic representation of calcium homeostasis regulated by 
PTH, calcitonin and 1,25- (OH)2 Vit D3 interaction.
Figure 1.14: Overview of Calcium Regulation.
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(iv) Calcitonin inhibition of bone resorption by directly inhibiting the activity of the 
mature osteoclast.
Although some investigators have proposed that PTH has a direct effect on 
osteoclasts 114,115 the conventional hypothesis considers it to be an indirect action. 
PTH is thought to act indirectly on osteoclasts by either stimulating osteoblasts H6, 
stromal cellsll7»H 8 0r other bone marrow cell types (e.g. mast cells), to secrete 
paracrine factors, such as interleukin-6 (IL-6) and IL-11 119-121  ̂which act locally. 
Alternatively, it may modulate cell-cell interactions between osteoblasts and 
osteoclasts 25,122 Osteoclast access to bone surfaces is enhanced by PTH induced 
retraction of bone lining cells from resorption sites 123
The potential anabolic actions of PTH were first recognised in 1922, when a study 
revealed that PTH extract could increase bone density in the young rat 124. Since then 
PTH has been shown to enhance bone formation in animal models 13.125-134 as wep 
as in the human 135-138 p j f j  induced bone formation increases bone 
strength 1 3 2 , 1 3  9 , 1 4 0  without  altering geometry and involves both 
trabecular 125,131,141,142 an(j cortical bone 125,143
The process of PTH induced bone formation has been attributed to increased
osteoblast proliferation and activity associated with increased levels of osteocalcin
and BMP gene expression  144-146 the activation and differentiation of bone lining
cells to osteoblast phenotype 15,16 an(j ^ e  stimulation of the proliferation and
differentiation of osteoprogenitor cells in the bone marrow 126. jn v[tro evidence
suggests that the PTH induced bone formation is mediated by local production of 
IGF-1129,147,148 or TGFp 129,149,150.
PTH mediates its effects through interaction with a receptor linked to a guanine 
nucleotide binding protein (G (s) protein(GDP)) 131 (fig. 1.15). In the resting state 
GDP is bound to the a  subunit of the protein, PTH binding induces a conformational 
change in the receptor causing it to bind to the G-protein. The activated G-Protein 
releases GDP and binds GTP (Guanine triphosphate) initiating the dissociation of the 
a , p and y subunits. The free a  subunit binds adenylate cyclase (AC), catalysing the 
synthesis of cyclic adenosine-5’-monophosphate (cAMP) from adenosine-5’- 
triphosphate (ATP) 146,152,153 CAMP dependant protein kinase, protein kinase A, 
(PKA) then phosphorylates gene regulating proteins.
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Depending on the pulse amplitude and frequency modulation of the applied PTH an 
additional signalling pathway may be activated. Binding of PTH can activate a G(p) 
protein coupled to PLC154 resulting in the hydrolysis of PIP2 to IP3 and DAG. 155. 
The production of IP3 leads to the release of intracellular calcium stores, and DAG 
activates PKC, inducing C-FOS gene expression 122,156-158 §ee figure 1.18 for 
signalling overview.
Previously it was thought that two separate PTH receptor classes were responsible for 
the activation of these separate p a t h w a y s  159 but more recent evidence from binding 
studies indicate only one class of PTH receptor is r e s p o n s ib le  154. it is now accepted 
that the differential modulation of the PTH stimulated PKA and PKC 
pathw ays 1^5,160 accounts for the opposing effects seen with different PTH treatment 
regimes.
PTH stimulation of bone formation is predominantly mediated via the PKA pathway 
109,125,142,144,161 although it is suggested a lesser involvement from the PKC 
pathway may also be required 144,161 Bone resorption however is modulated chiefly 
by the PKC pathway 119,162 with some contribution from the PKA pathway 112.
The ability of the PTHr to activate multiple signalling pathways depends, at least in 
part, on the presence of different functional domains in the PTH molecule. The 
resulting structure : function studies can be summarised as follows:
The C terminal fragments are biologically inactive 163. Fragment AA1-7 activates
PKA pathway when some part of the 25-34 region is also presen t 109,164 Region
A A 1-31 stimulates PK A  o n ly !0 9 ,1 4 1 ,1 4 4 ,1 6 5  and A A 28-33 stimulates PK C  and
mitogenic activity 109,164 Roth the PKA and PKC pathways are induced by PTH
fragment AA1-34 and the intact hormone A A l - 8 4 l 0 9 , 1 2 5 , 1 4 4  The anabolic effect of
PTH is diminished by removal of AA1 and abolished by removal of A As 1+2 
109,164
Intracellularly, activation of the PKA pathway is associated with bone formation 
while activation of the PKC path is related to resorption. Accepting that activation of 
the PKA and PKC pathways are associated with particular domains of the PTH 
molecule it can be deduced that a relationship exists between PTH treatments and the 
PTH domain which binds the receptor. The mechanics of this correlation are not 
understood.
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As can be seen, the effect of PTH on bone cell activity is wide ranging and somewhat 
contradictory, although it is widely accepted that the osteogenic effects of PTH are 
related to intermittent treatments and the osteolytic effects with chronic applications. 
These findings have indicated that a PTH fragment could eventually become the basis 
of novel treatments for osteoporosis and other conditions of bone deficit, and, 
consequently has stimulated research interest in that area 166,167
1.3.2: Other Hormones Influencing Bone Turnover.
The naturally occurring corticosteroid, cortisol is produced in the adrenal cortex. 
Synthetic derivatives of cortisol, (e.g. dexamethasone (Dx), prednisone, prednisilone) 
have potent anti-inflammatory and immunosuppressant effects and are commonly 
used in the treatment of asthma, cardio-vascular disease and inflammatory bowel
disease 168.
Glucocorticoids exert significant effects on bone metabolism via classical 
glucocoricoid receptors 169,170 Unlike other hormones (except thyroid) steroids pass 
through the cell membrane by diffusion and bind to specific receptor proteins in the 
nucleus. The hormone receptor complex (HRC) then binds to specific DNA 
sequences called Hormone Responsive Elements (HREs). The HREs then either 
enhance or suppress the expression of specific genes adjacent to the HREs.
In vivo glucocorticoids stimulate bone resorption and inhibit formation leading to an 
overall bone deficit 1^1. Patients subjected to long term treatment with glucocorticoid 
suffer significant bone loss 172-174 jjjg  mechanisms by which glucocorticoids 
modulate these effects are complex and beyond the scope of this review. Briefly, 
glucocorticoids affect nearly every system in the body and those systems that 
modulate bone remodelling are overviewed in table 1. 4168 .
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Table 1.4.
Effects of Glucocorticoids on Systems that Modulate Bone Remodelling.
Pituitary
Inhibition of secretion of:
Growth Hormone
Follicle Stimulating Hormone/Luteinising Hormone 
Adrenocorticosteroid Hormone
Cellular Transport





Increased peripheral sensitivity to PTH
Gonads
Inhibition of the synthesis of:
Estrogen by ovary 
Testosterone by testes
Adrenal
Decrease in secretion (due to suppression of ACTH) of: 
Dehydroepiandrosterone 
Androstenedione
In vitro, glucocorticoids may either stimulate of inhibit bone formation. In order to 
understand this paradox it is important to distinguish between the development and 
the regulatory effect of glucocorticoids on bone metabolism.
It is suggested that glucocorticoids first cause the proliferation and differentiation of a 
distinct population of osteoprogenitors cells that participate in bone formation 175- 
180 then in more differentiated cells, limit further proliferation 181. It can be seen 
therefore that the effects of glucocorticoids in culture systems are dependant on the 
timing of the addition of the hormone coupled to the stage differentiation of the cells.
Glucocorticoid effects on bone metabolism can be direct or indirect. Directly, 
glucocorticoids modify the expression of C-Fos and C-Jun whose relative ratios 
regulate the expression of other genes 171, as well as the expression of osteoblast 
specific genes such as osteocalcin and collagen Type I.
Indirectly, glucocorticoid effects may be due to the modification in the synthesis of 
activity of growth factors secreted by bone. IGF-1 and TGFp are important bone 
modulating growth factors whose expression and activity are affected by 
glucocorticoid treatment. Glucocorticoid treatment stimulates osteoblasts to activate
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latent TGFp 182 ancj decrease its mitogenic properties in bone cells 183 xhe activation 
of TGF p by glucocorticoids in bone cells may be relevant to the actions of the steroid 
on bone resorption.
The expression of IGF-I but not IGF-II, is directly down regulated by glucocorticoids 
and it is likely that the inhibitory action of steroids on IGF-I synthesis is related 
to its effects on bone formation. The effects of glucocorticoids on other important 
bone modulating factors, the FGFs, BMPs and PDGF, are currently unknown 503}.
Insulin. Insulin is a polypeptide hormone synthesised by the P cells of the pancreas. 
Its main effect on bone remodelling is the stimulation of bone matrix synthesis and 
cartilage formation without affecting cell proliferation. This suggests that its effect is 
on the differentiated function of the osteoblast. Although insulin has direct 
stimulatory effects on bone tissue it also increases IGF production by the liver, 
therefore, some of the in vivo effects of insulin may be mediated by IGF. Insulin has 
no effect on bone resorption 10
Growth hormone Growth hormone is a pituitary polypeptide which does not have a 
direct effect on bone resorption but, is thought to affect bone formation by direct 
stimulation of osteoblast activity and indirect stimulation of IGF synthesis. Growth 
hormone is essential for the maintenance of normal bone mass 185.
Estrogens and androgens. Estrogens and androgens are important for the prevention 
of bone loss and the maturation of the skeleton. The anti-resorption effect estrogen is 
thought to be mediated via the down regulation of cytokines such as interleukin-6 , a 
potent resorption p r o m o te r  186.
Thyroid hormone. Thyroid hormones have no effect on bone matrix synthesis or 
osteoblast proliferation but are known to stimulate resorption. They also play an 
essential role in cartilage formation and are therefore important for normal 
development and growth 10.
1.3.3: Cytokines.
A number of cytokines which exert important effects in the immune and 
haematopoietic systems are produced by, and also influence the activities of skeletal 
cells. These include EL-1, IL-6 , macrophage and granulocuyte/macrophage colony 
stimulating factors and tumour necrosis factor (TNF).
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IL-1 has complex effects on bone remodelling and stimulates both bone cell 
replication and bone resorption 187 IL-1 also increases the synthesis of IL- 6  which 
increases bone resorption through the recruitment of cells in the osteoclast lineage.
IL- 6 synthesis is inhibited by estrogens and this effect could explain the decrease in 
bone resorption following estrogen therapy 188 TN F-a stimulates bone resorption, 
bone cell replication and inhibits osteoblastic d i f f e r e n t i a t i o n !  89 Colony stimulating 
factors play a role in the maturation of osteoclasts, and granulocyte/macrophage- 
colony stimulating factor secretion is stimulated by PTH.
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1.4: In Vitro Models of Differentiation.
As bone retains the capability to remodel, reform and repair throughout life, a 
reservoir of progenitors for bone forming and resorbing cells is required. An 
investigation of the factors that regulate this stem cell pool and induce commitment 
to, and expansion of, the osteogenic, or the adipogenic population may lead to an 
understanding of osteoblast decline in osteoporosis.
It is well established these osteogenic precursors exist in association with the
soft connective tissue of the marrow stroma 190 an(j it is proposed that these
precursors are commonly shared by cells of other types 191.
A popular thesis proposes that adipogenic, reticular and fibroblastic cell lines are all 
derived from the same progenitor cell type as osteogenic cells (fig. 1.16).
Numerous studies have demonstrated that when suspensions of bone marrow cells are 
plated in vitro, clonal colonies of fibroblastic shaped cells are formed 169,190-194 
Each colony is derived from a single (self-renewing) initiating a cell type termed a 
Colony Forming Unit Fibroblastic (CFU-F) 195. Importantly, a proportion of these 
cells when transplanted in vivo , exhibit the characteristics of stem c e l l s  196. Jt is 
thought that CFU-Fs with high proliferative capacity represent the primitive stem 
c e l l  197 while colonies with lesser capacity represent cells at later stages of 
differentiation 198.
Presently, knowledge of the commitment steps from early stem cells, to committed 
osteoprogenitor, through to pre-osteoblast and osteoblast is relatively weak 11. An 
understanding of the markers associated with the different stages of osteoblast 
differentiation will provide new insights into the nature of the osteoblast and its 
lineage relationship. Figure 1.17 represents an overview of the osteoblastic stage 
specific markers utilised in this study and are summarised below.
1.4.1: Osteoblastic Markers.
Alkaline phosphatase (AP). (orthophosphoric-monoester phosphohydrolase, alkaline 
optimum) is a protein ubiquitous in nature whose exact physiological functions are 
unknow n 199 T he enzyme is covalently bound to phosphatidyl inositol (PI) 
phospholipid complexes in the plasma membrane where it functions to hydrolyse 
monophosphate esters at a high pH 12.
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Figure 1.16: Proposed Marrow Stromal Cell Lineages. (Adapted from Owen 191).
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60
In the human, three tissue associated alkaline phosphatase isoenzymes exist: 
intestinal, placental, and germ cell (placental-like), along with a fourth more widely 
distributed isoform known as bone/liver/kidney alkaline phosphatase or tissue-non­
specific alkaline phosphatase (AP)200 The four isoenzymes are encoded by four 
distinct genes200, the bone/liver/kidney subtypes of AP differing only in post- 
translational carbohydrate modification of identical polypeptide sequences201
Identification of AP gene mutations in hypophosphatasia, a rare inborn error of 
metabolism which causes defective skeletal mineralisation, has confirmed the 
hypothesis that AP executes specific important functions in the process of skeletal 
mineralisation 199. Analysis of serum from patients suffering from hypophosphatasia 
reveals normal enzyme activity in the three tissue specific isoforms of AP, but in the 
AP isoenzyme, a generalised reduction in activity is recorded,202 indicating that the 
tissue-non-specific form of AP plays an important part in the mineralising process.
Although the precise mechanism by which AP modulates the mineralising process is 
unclear, a number of theories have emerged which may contribute to our 
understanding in this area:
AP hydrolyses nucleoside phosphate (liberated by dying cells) to increase the 
local concentration of inorganic phosphate (Pi) 203.
A P acts in biomineralisation by hydrolysing an inhibitor of calcification^OO
AP can act as an inorganic pyrophosphatase (PPi). At high concentrations PPi 
inhibits the growth of hydroxyapatite crystals204.
AP acts as a plasma membrane transporter for Pi and a extracellular
calcium binding protein that stimulates calcium phosphate precipitation into
osteoid 205
Uncertainty surrounding the precise function of AP has not impinged upon its 
widespread acceptance as a marker of osteogenic differentiation. It is accepted that, as 
the specific activity of AP in a population of cells increases there is a corresponding 
shift to a more differentiated state 12 and as such, is routinely used in in vitro 
experiments as a relative marker of osteoblast differentiation 14,206,207
STRO-1 is a monoclonal antibody that recognises a trypsin resistant cell surface 
antigen expressed by a subset of human marrow stromal cells that includes all
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assayable CFU-F. STRO-1 positive cells proliferate extensively in culture and give 
rise to cells of a variety of marrow stromal cell lineages 208. These findings are 
consistent with the possibility that the STRO-1 population contains the primitive 
multipotential stem cells. The STRO-1 antigen is therefore the subject of much 
research and its antibody provides a useful investigative tool in this area.
CBFA1 is a recently discovered transcription factor that belongs to the core-binding 
factor f a m i ly  209 To date, three CBFA genes, all belonging to the Runt domain gene 
family, have been identified: CBFA1, CBFA2 and CBFA3210-213. CBFA1 
knockout mice are bom with a total lack of both membranous and endochondral bone, 
an absence of osteoblasts and extremely low expression of osteoblast associated 
genes^H (alkaline phosphatase, osteopontin, osteocalcin) suggesting a key role for 
this factor, in early osteoblast development. This suggestion is supported by evidence 
that in the embryo, CBFA1 expression is located both temporally and physically, at 
sites of early bone d eve lopm en ta l 0,211 CBFA1 also binds specifically to OSE2, a 
unique osteoblast specific regulatory element found in the promoter region of all 
osteoblast associated genes 210. Binding to this element induces osteoblast specific 
transcription and this effect further enhances the thesis that CBFA1 expression 
represents a specific marker of osteoblastic lineage.
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Figure 1.17. Proposed Lineage Markers for Cells of the Osteoblastic Lineage
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Key: ? = Unknown; — — = Not Detected; = Present.
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The concept of the CFU-F as a multipotential mesenchymal precursor provides a 
useful model in the study of in vitro bone cell biology. The recognition that CFU-F 
differentiation can be modified at the colony level in vitro , presents an opportunity 
to investigate the plasticity of differentiation between mesenchymal lineages using 
different factors and conditions in culture.
Because there are important differences between human and experimental animal cell 
culture systems, this study will focus on the use of human cells. The rationale is that
human cells are most appropriate for in vitro work relating to human disease.
This investigation will attempt to identify factors which promote cells to the 
osteogenic pathways of differentiation and promote the proliferation of osteogenic 
cells in cultures derived from human bone marrow.
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Chapter 2: Materials And Methods.
2.1: Materials.
2.1.1: Fixatives.
All component parts of periodate-lysine-paraformaldehyde fixative as well as 
paraformaldehyde were obtained from Sigma-Aldrich (Poole, UK). Methanol was 
supplied by Hayman PLC (Witham, UK).
2.1.2: Growth factors.
Fibroblast growth factor -2 (FGF-2) was obtained from NBS Biologicals, Insulin-like 
growth factor I (IGF-I) and Transforming growth factor (31 (TGFp-1) were purchased 
from Sigma-Aldrich (Poole, Dorset UK).
2.1.3: Hormones.
Human Parathyroid hormone (fragment 1-34) was obtained from both Sigma-Aldrich 
and Eli-Lilly (Indiana, Ind. U.S.A.). Insulin was supplied by Sigma-Aldrich.
2.1.4: Immunochemicals.
The monoclonal antibody (Mab) (IgM subclass) STRO-1208 ? derived from the 
hybridoma cell line STRO-1 was a gift from Dr Paul Simmons, Hanson Centre for 
Cancer Research (IMVS, Adelaide, South Australia). The STRO-1 Mab was used in 
the form of undiluted tissue culture supernatant. Hybridoma B4-78^14 (igGl 
subclass) which recognises the TNSAP isoenzyme of alkaline phosphatase was 
obtained from Developmental Studies Hybridoma Bank (University of Iowa, Iowa 
City, IA, USA). Antibody from hybridoma B4-78 was purified from culture 
supernatant by protein G chromatography.
Hybridoma culture supernatant from an IgM-secreting hybridoma reactive with an 
intracellular antigen OBL^IS and non-immune mouse IgGl were obtained from 
Sigma-Aldrich and used as negative controls.
Fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgM and R-phycoerythrin 
(RPE)-conjugated anti-mouse IgGl were supplied by AMS Biotechnology, (Oxon. 
UK).
2.1.5: Kits.
Messenger Ribonucleic Acid (mRNA) was extracted from cells using the Quickprep 
Micro mRNA Purification kit supplied by Pharmacia Biotech (St Albans UK).
Protein concentration was determined using the Bio-Rad DC Protein assay obtained 
from Bio-Rad Laboratories (Hemel Hempstead, UK).
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Intracellular cAMP levels were measured using the Biotrak cAMP enzyme 
immunoassay system supplied by Amersham Pharmacia (Little Chalfont, UK).
2.1.6: Molecular Biology Reagents.
Reverse transcriptase with associated buffer, RNAguard RNase inhibitor and 
Dithiothreitol (DTT) were all purchased from Gibco Life Sciences (Paisley, UK), 
reverse transcriptase random hexamer primer, (Pd(N)6 ), and deoxynucleotide- 
triphosphates (dNTPs) were supplied by Amersham Pharmacia. Thermus aquaticus 
(Taq) DNA polymerase, Taq buffer, DNA markers (4>x Hae cut and X Hind III cut) 
and magnesium chloride (MgCl) were obtained from Promega PLC (Southampton, 
UK). Agarose and ethidium bromide (EtBr) was supplied by Sigma-Aldrich. T4 
polynucleotide kinase (PNK) and PNK buffer were supplied by New England Biolabs 
(Beverly, MA. USA), [y-32 P] dATP and Hybond-N+ were purchased from 
Amersham Pharmacia. Oligonucleotide primer and probe sequences were obtained 
from Colin Lazarus (Dept, of Botany, University of Bristol, U.K.)
2.1.7: Staining Reagents.
Methylene Blue, Fast Red TR, alkaline buffer, napthol AS-MX phosphate and Di- 
methylformamide were all obtained from Sigma-Aldrich.
2.1.8: Tissue Culture Reagents.
Dulbecco’s modified Eagles medium, sodium bicarbonate, Hepes buffer, L- 
glutamine, sodium pyruvate, trypsin-EDTA and penicillin/streptomycin were all 
obtained from Gibco (Paisley, UK). Fetal calf serum (FCS) was supplied by 
Globepharm PLC. (Esher, UK). L-ascorbate-2-phosphate ( A s p ) 2 1 6  was purchased 
from Alpha Laboratories (Eastleigh, Hants. UK). Dexamethasone (Dx), collagenase 
type VII, dimethylsulfoxide (DMSO), and DNAase I were obtained from Sigma- 
Aldrich.
Ficoll Lymphoprep (density: 1.077g/ml), was supplied by Nycomed PLC 
(Birmingham, UK). Phosphate buffered saline tablets (PBS) (pH 7.4, calcium and 
magnesium free) were purchased from Oxoid (Bristol, UK). Tissue culture flasks and 
associated plastics (cell strainers, filters etc.) were obtained from Becton and 
Dickinson Labware (Oxford, UK) and Fahrenheit Lab Supplies (Milton Keynes).
SaOs cells were obtained from ATCC (Manassa, VA. U.S.A.)
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2.1.9: Other Reagents.
Alkaline buffer, bovine serum albumin (Fraction V) (BSA), diethylpyrocarbonate 
(DEPC), disodium para-nitrophenol, sodium azide and sodium hydroxide (NaOH) 
were all supplied by Sigma-Aldrich.
Human AB serum was purchased from IBRGL Research Products (Elstree, UK), 
Isopropanol and hydrochloric acid (HC1) and glacial acetic acid were supplied by 
Hayman PLC (Witham, UK) and isoton was obtained from Coulter Electronics 
(Luton, UK).
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2.2: Preparation of Media and Solutions.
2.2.1: Dulbecco’s modified Eagle’s medium + 10% (v/v) fetal calf serum (standard
medium).
Final Cone.
Dulbecco's modified Eagles medium (X10) 100.0 mis 10%
Sodium Bicarbonate (7.5%) 11.4 mis 0.085%
Hepes (1M) 20.0 mis 0.02M
Glutamine (200 mM) 10.0 mis 0.002M
Sodium Pyruvate (100 mM) 10.0 mis 0.001M
Penicillin/Streptomycin (104 IU/ml) 2.5 mis 25 IU/ml
Heat inactivated FCS 100.0 mis 10%
In a flow hood using aseptic technique, the above reagents were combined and made 
up to 1 litre with Milli Q sterile H2O. The pH was adjusted to 7.3 using 5M NaOH 
and the total volume filter sterilised using a 0.22jiM pore size bottle top filter. 
Sterility was confirmed by incubating a 5ml sample for 48 hrs at 37 °C in a humidified 
atmosphere containing 5% CO2.
2.2.2: Blocking Buffer.
Human AB serum 1.0 ml (10% (v/v))
Bovine serum albumin (BSA) 0.1 mg (1% (v/v))
FCS 0.5 ml (5% (v/v))
The above reagents were made up in HBSS (8.4 mis) to a total volume of 10 mis.
2.2.3: Elution Buffer (Supplied with Ouickprep Micro mRNA Kit).
Tris-HCl (pH 7.5) 10 mM
EDTA 1 mM
2.2.4: Extraction Buffer (Supplied with Ouickprep Micro mRNA Kit). 
Buffered aqueous solution containing guanidinium thiocyanate and N-lauroyl 
sarcosine.
2.2.5: Freezing Solution.
FCS 50 mis (50% (v/v))
DMEM 30 mis (30% (v/v))
DMSO 20 mis (20% (v/v))
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2.2.6: Glycogen Solution fSupplied with Ouickprep Micro mRNA Kit). 
Glycogen lOmg/ml
Made up in DEPC treated water.
2.2.7: Hank’s Buffered Saline Solution (HBSS1
HBSS was obtained from Gibco Life Sciences (Paisley, UK).
2.2.8: High Salt Buffer fSupplied with Ouickprep Micro mRNA Kit).
Tris-HCl (pH 7.5) 10 mM
EDTA ImM
NaCl 0.5M
2.2.9: K Acetate Solution (Supplied with Ouickprep Micro mRNA Kit).
Potassium Acetate (pH 5.0) 2.5 M
2.2.10: Low Salt Buffer (Supplied with Ouickprep Micro mRNA Kit).
Tris-HCl (pH 7.5) 10 mM
EDTA ImM
NaCl 0.1M
2.2.11: Phosphate Buffered Saline (PBS).
Five PBS tablets were dissolved in 500 ml Milli Q micronised water and the solution 
autoclaved.
2.2.12: Saline Sodium Citrate fSSC) f20Xl.
Sodium chloride 175.3 g
Sodium citrate 88.2 g
The above reagents were dissolved in 800 ml of H2O and the pH adjusted to 7.0 with 
a few drops of 10N NaOH. The final volume was adjusted to 1 litre and the solution 
sterilised by autoclaving.
2.2.13: Serum free media.
Sodium Selenite (NaS) (2pg/ml) 1 ml (20ng/ml)
Human Apo-Transferrin (0.5mg/ml) 1 ml (5 jig/ml)
BSA-Linoleic acid (5mg/ml) 100|il (5|Lig/ml)
DMEM was added to a total volume of lOOmls and the solution was then filter 
sterilised using a 0 .22jim pore size, bottle top filter.
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2.2.14: Sodium dodecvl sulphate (SDS) (10% (w/vfi.
Sodium dodecyl sulphate (electrophoresis-grade) 100 g (10% (w/v)).
H2O 900 ml (90% (v/v))
The reagents were heated to 6 8°C to assist dissolution, pH was adjusted to 7.2 using a 
few drops of concentrated HC1. The final volume was then adjusted to 1 litre.
2.2.15: Tris-Acetate (TAE) (IPX).
Tris base 48.44 g (0.4 M)
Sodium acetate 4.10 g (0.05 M)
EDTA (0.5 M, pH 8.0) 3.72 g (0.05 M)
The above were dissolved in (IH2O to a final volume of 1 litre and the pH adjusted to 
8.1 with glacial acetic acid.
2.2.16: Tris-Borate Buffer (TBE) (5X).
Tris base 54.0 g (0.445 M)
Boric acid 27.5 g (0.445 M)
EDTA (0.5 M, pH 8.0) 20.0 ml (0.01 M)
The reagents were dissolved in dH2 0  and made up to a final volume of 1 litre.
2.2.17: Wash Buffer /Flow Cvtometryl.
HBSS 950 ml (95% (v/v))
FCS 50 ml ( 5% (v/v))
2.2.18: Human Platelet Poor Plasma (PPP).
Human platelet poor plasma was always prepared fresh for immediate use according 
to the following protocol: Donor lying down and rested. Using a syringe and needle, 
not a vacutainer, 50 ml of whole blood is taken and gently transferred to a Falcon 
tube containing trisodium citrate as anticoagulant (0.105 M at 1:8 ratio in sample). 
The sample should then be processed as soon as possible.
Centrifuge at lOOOg for 30 mins at 0°C. Remove the plasma, add to fresh tube then 





Unless otherwise described, all procedures described were carried out using aseptic 
technique in a Microflow category II flow hood. All cell types were cultured at 37°C 
in humidified atmosphere comprising 95% air, 5% CO2.
Preparation of bone marrow mononuclear cells 1BMSC1
Bone marrow was obtained from segments of rib removed during routine thoracic 
surgery at Frenchay Hospital, Bristol. Patients used for this study had no history of 
metabolic bone disease or treatment with drugs known to affect bone metabolism. 
Samples were obtained in accordance with procedures approved by the local ethics 
committee.
In a flow hood, using aseptic technique, the ribs were cleared of all extraneous 
muscular and connective tissue. The ribs were then divided and the marrow cavity 
and flushed using PBS. The resulting cell suspension was centrifuged at 500g for 10 
mins. BMNC were isolated from the cell pellet following resuspension and density 
gradient centrifugation on Ficoll Lymphoprep (600g, 30 mins). The BMNC layer was 
extracted from the Lymphoprep/PBS interface, washed twice in PBS by  
centrifugation (500g, 10 mins) and a suspension of single cells obtained by filtration 
through a 45 [im pore size, cell strainer. Cell numbers were determined using a 
Coulter Counter electronic cell counter (Coulter Electronics PLC, Luton UK).
Maintenance of Cells.
BMNC and SaOs-2 cells were initially seeded in culture flasks at a density of 2 X 
lO^cm2 in standard medium supplemented with 100pm ascorbate-2 -phosphate and 
test factors. After 7 days in culture the non-adherent cells were removed and the 
medium replenished twice weekly thereafter.
Passaging and Harvesting of BMNC .
When passaging or harvesting cells, the medium was removed and the cell layer 
rinsed twice with PBS. The cells were then incubated with DMEM (10mls/T75) 
containing 30 IU/ml collagenase type VII and 2mM additional Ca++ for 1 hour at 
37°C. Following the removal of the collagenase solution the cells were washed twice 
with PBS and then incubated with 0.02% trypsin-EDTA (5mls/T75) for 5 mins. After 
checking that cell detachment had occurred, the trypsin reaction was terminated by
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the addition of 1% (v/v) FCS. A single suspension was achieved by gentle pipetting 
and straining using a Falcon 70|im  cell strainer. The cells were then harvested, 
washed in PBS by centrifugation (5 min, 500g) and counted.
Passaging Cell Lines.
When passaging SaOs cell lines the collagenase step was omitted.
Freezing of cells.
Cells were harvested, washed and counted, then resuspended in 50% (v/v) FCS / 50% 
(v/v) DMEM to a concentration of 1 X 106 /ml . 500(il aliquots of the suspensions 
were placed in freezing vials where freezing solution was added in a dropwise fashion 
to a total volume of 1 ml. Vials were then cooled slowly overnight to -70°C before 
transfer to storage in liquid nitrogen .
To set up cells from frozen, a vial was removed from the liquid nitrogen and rapidly 
defrosted by clasping in the hand. The vial was then washed in 70% (v/v) ethanol 
before the cells were removed and washed twice in DMEM by centrifugation (500g, 
10 mins). The cells were then plated into culture flasks containing standard medium 
and re-established in culture and expanded. These cells were then harvested for use in 
experiments.
2.3.2: Bioassavs.
Alkaline Phosphatase (API Activity Assay.
Cellular alkaline phosphatase activity was measured colorimetrically by monitoring 
the release of para-nitrophenol (p-nitrophenol) from disodium p-nitrophenol 
phosphate at 37 °C, pH 10.5. The reaction produces a coloured product which can be 
measured spectrophotometrically at 410 nm.
Cells were cultured for various times under test conditions in 96 well plates. At the 
end of the treatment period, the medium was removed and the cells washed twice in 
PBS. Alkaline buffer (lOOpl/well) was added and incubated at 37°C for 30 min. 
Phosphatase substrate containing 4mg/ml disodium p-nitrophenol phosphate was 
prepared in ddH20 containing 2pM MgCl and added to the wells (100|il/well). A set 
of standards using known concentrations of p-nitrophenol in alkaline buffer in the 
range l-200nM, was set up on the plate in parallel. Blanks were prepared by adding 
100|L11 of alkaline buffer to 100 j llI  of substrate solution.
A further incubation at 37 °C continued until the colour intensities of the samples 
were comparable with the standards. The reaction was then stopped using 50|il, 1M
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NaOH/well and the incubation time recorded. The absorbance was read at 410nm on 
a Dynatech MR5000 plate reader and enzyme activity, expressed as nMol/p- 
nitrophenol/min, determined from the standard curve (fig. 2 .1).
cAMP Assay.
Intracellular cyclic adenosine monophosphate (cAMP) was assessed using the Biotrak 
cAMP enzymeimmunoassay (RPN 225) supplied by Amersham Life Sciences.
The basis of this assay is the competition between unlabelled cAMP and a fixed 
quantity of peroxidase-labelled cAMP. The labelled and unlabelled cAMP compete 
for a limited number of binding sites on a cAMP antibody. With fixed amounts of 
antibody and peroxidase-labelled cAMP the amount of peroxidase-labelled ligand 
bound by the antibody will be inversely proportional to the concentration of added 
unlabelled ligand. The peroxidase ligand that is bound to the antibody is immobilised 
on to polystyrene microtitre plates precoated with second antibody (fig. 2 .2a), thus 
the unbound ligand can be removed by a simple washing procedure
The amount of peroxidase labelled cAMP bound to the antibody is determined by the 
addition of a tetramethylbenzidine (TMB)/hydrogen peroxide single pot substrate The 
reaction is stopped by the addition of an acid solution, the resultant colour read at 450 
nm in a microtitre plate spectrophotometer.
Concentration of cAMP in f/Mol was determined from a standard curve generated as 
part of the assay (fig. 2.2b). cAMP concentrations were then normalised to fMol/mg 
cell protein, using the Bio Rad DC protein assay.
Preparation of Cells for cAMP Assay.
Cells to be assayed were plated at a density of 1.25 x 105 cells/well in a 24 well plate 
and left overnight to adhere in standard culture conditions. The following day at T - 
15 mins the media was removed and replaced with serum free medium (SFM) 
containing 500|iM iso-butyl-methyl-xanthine (IBMX). At T = 0 the SFM/IBMX 
media was removed and replaced with SFM/IBMX containing the PTH treatments. 
The reaction was terminated at T +15 mins by the addition of absolute ethanol to 66% 
(v/v) at a temperature of -20 °C. The ethanol extract was removed and added to a 5 ml 
microfuge tube, then spun at 500g for 10 mins at 4°C. The ethanol supernatant was 
then evaporated on a Jouan RC. 10.22 rotary evaporator at 50°C for 6 hours using a 
pulsed vacuum. The resulting extract was dissolved in assay buffer and assayed 
according to kit instructions.
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Figure 2.1: A Typical Standard Curve for the AP Activity Assay
O.D. 
(410 nM)









Figure 2.2a: Schematic Representation of Antibody Binding in the Biotrak cAMP
Assay
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Figure 2. 2b: Typical Standard Curve for the cAMP Assay
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Bio-Rad DC Protein Assay
Bio-Rad DC Protein Assay is a colorimetric assay used to determine protein 
concentration following detergent solubilisation. The reaction is similar to the well 
documented Lowry Assay217
The assay is based on the reaction of protein with an alkaline copper tartrate solution 
and Folin reagent. As with the Lowry assay, there are two steps which lead to colour 
development: The reaction between protein and copper in an alkaline medium and the 
subsequent reduction of Folin reagent by the copper treated p r o t e i n ^ l S  Colour 
development is primarily due to the amino acids tyrosine and tryptophan, and to a 
lesser extent, cysteine and histidine. Proteins effect a reduction of the folin reagent by 
a loss of 1, 2 or 3 oxygen atoms, thereby producing one or more several possible 
reduced species which have a characteristic blue colour with maximum absorbance at 
750nM and minimum absorbance at 405nm.
Samples were set up in triplicate and cultured for various times under test conditions 
in 96 well plates. At the end of the treatment period, the medium was removed and 
the cells washed twice in PBS. To each well was then added 25 p i of alkaline tartrate 
solution and 200 p i of a dilute folin reagent (both reagents supplied with kit). After 
15 minutes at room temperature the absorbance was read at 750nm and protein 
concentration determined from a standard curve.
The standard curve was set up using triplicate BSA protein concentrations in the 
range 0.25 mg/ml - 4 mg/ml. Figure 2.3 shows a typical standard curve.
MTT Rapid Colorimetric Assay
Cell proliferation was measured in 96 well plates using MTT (3-(4,5 Dimethylthiazol- 
2y)-2,5-diphenyl tetrazolium bromide), a pale yellow substrate which produces a dark 
blue formazan product when incubated with live cells 19. The amount of formazan 
product produced is directly proportional to the number of live cells. The formazan 
product is only partly soluble in the medium and must be dissolved to produce a 
homogenous solution suitable for measuring its optical density.
Samples were set up in triplicate and cultured for various times under test conditions 
in 96 well plates. At the end of the treatment period, the medium was removed and 
the cells washed twice in PBS. 20 |il of MTT (5mg/ml) was then added to each well 
and incubated for 4 hours at 37°C. The reaction was then stopped using lOOjul, 10% 
SDS.
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Figure 2.3: Typical Standard Curve for the Biorad Protein Assay
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Figure 2.4: A Typical Standard Curve for the MTT Proliferation Assay.
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in 0.01M HC1. Dissolution of insoluble MTT component was achieved by overnight 
incubation in the SDS solution. The optical density was then read on a Dynatec plate 
reader using a reference wavelength of 630nm and a test wavelength of 570nm.
Optical density is directly proportional to cell number thus allowing direct 
comparisons of proliferation to be made.
2.3.3: Flow Cytometry.
Flow cytometry analysis was carried out on a Becton Dickson FACStar Plus flow 
cytometer, equipped with a 488nm, lOOmW argon ion laser and Consort computer. 
Flow cytometry allows the rapid measurement of multiple cellular parameters based 
on light scatter and fluorescence in a stream of cells passing through a laser 
illuminated sensing point^^O (fig. 2.5). Laser illumination of specific wavelength 
excites fluorescent dyes (e.g.. fluorescein isothiocyanate (FITC) and R-phycoerythrin 
(PE) conjugated to the cell and the resulting scattered and fluorescent light is 
collected by photodetectors and converted into electronic signals. Optical filtration 
permits the separation of scattered and fluorescent light allowing specific, 
independent but correlated measurements to be made.
Measurements of forward scattered light (FSC) relate to cell size and side scattered 
light (SSC) values relate to cell granularity. Conjugation of fluorescent dyes to 
ligands and antibodies enables the density and distribution of cell surface and 
cytoplasmic determinants to be studied. Data was collected as either dot plots or 
frequency histograms (fig. 2.6). Dot plots consisted of SSC versus FSC graphs 
allowing the identification of discrete cell populations, or FL1 (FITC channel) versus 
FL2 (PE channel). Histograms generally depicted fluorescence intensity..
Preparation of Cells for Flow Cvtometrv.
Cells were cultured for differing times under various test conditions in T75 culture 
flasks. At the end of the treatment period the medium was removed and the cells 
washed twice in PBS, then harvested as previously described.
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(a) Typical dot plot.
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Immunolabelling of Cells for the Detection of STRO-1 and AP Expression.
Cells were immunolabelled with monoclonal antibodies recognising either the STRO- 
1 antigen (STRO-1), the AP antigen (B4-78) or both. After harvesting, the cells were 
washed once in wash buffer and pelleted by centrifugation (400g, 5 mins). The cells 
were then incubated on ice for 30 mins in blocking buffer to reduce non-specific 
antibody binding. The cells were then aliquoted into 5 ml FACS tubes at 1 x 105 
cells/tube and washed by centrifugation (400g, 5 mins) with 4 mis of wash buffer. 
The buffer was aspirated and the cells incubated for 1 hour on ice with saturating 
concentrations of mouse IgGl in STRO-1 Mab (20pg/ml) and/or B4-78 Mab in OBL 
(20pg/ml). Mouse IgGl in OBL (20 |Lig/ml) was used in the negative controls.
The cells were then washed with 4 mis of ice cold wash buffer by centrifugation 
before the addition of 200 Jill of a combination of optimally diluted FITC conjugated 
anti-mouse IgM jx-chain specific (1/50 dilution in wash buffer) and PE-conjugated 
goat anti-mouse IgG2a specific (1/200 dilution in wash buffer) immunoglobulins. The 
cells were incubated for 45 mins on ice and then washed by centrifugation (500g, 5 
mins) before being analysed by flow cytometry. For dual labelled samples, 
compensation parameters were set using cells stained solely for STRO-1 or AP 
expression.
In all flow cytometry experiments, data acquisition and analysis were performed 
using the LYSYS II ™  and CELL QUEST software packages.
2.3.4: Preparation and Analysis of mRNA and DNA.
mRNA Extraction.
mRNA extraction was achieved using a Quickprep Micro mRNA Purification Kit 
(Pharmacia, St Albans U.K.). Briefly, the cells were harvested as previously 
described and extracted in a buffered solution containing a high concentration of 
guanidinium thiocyanate (GTC), this ensured the rapid inactivation of endogenous 
ribonucleic acid nucleases (RNases). The extract was then diluted three-fold with 
Elution Buffer, reducing the GTC concentration to a carefully selected level allowing 
the efficient hydrogen-bonding between poly(A) tracts on the mRNA molecules and 
oligo (dT) attached to cellulose. The extract was then clarified by a short 
centrifugation and the supernatant transferred to a microfuge tube containing oligo 
(dT) cellulose.
After several minutes, during which the poly (A)+ RNA binds to the oligo (dT) 
cellulose, the tube was centrifuged at 16,000g for 10 seconds, and the supernatant
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removed. Subsequent washes (3 X 0.5 ml) in both high and low salt buffers were 
followed by the elution of mRNA from the cellulose using pre-warmed elution buffer 
(0.2ml X 2). mRNA was then concentrated by precipitation with the addition of IO jllI 
of glycogen solution, 40 JJ.1 of K acetate solution and 1 ml of 95% (v/v) ethanol (- 
20°C) to 400pl of sample. The sample was then placed at -80°C overnight. 
Precipitated mRNA was then collected by centrifugation at 16,000g for 5 mins at 
4°C. After aspirating the supernatant, the mRNA pellet was re-dissolved in DEPC- 
treated water.
The concentration of mRNA following the precipitation step was determined by 
spectrophotometry. lOpl aliquots were diluted to 250 p i in DEPC treated water and 
the absorbances read at 260 and 280nm in a LKB Ultraspec II spectrophotometer and 
the A260/A28O ratios calculated. A ratio of 2.0 is expected, lower values indicate 
impurities or contamination by protein.
Reverse Transcription of mRNA.
mRNA was reverse transcribed to form cDNA prior to amplification in the 
polymerase chain reaction (PCR). 100 ng of mRNA was added to an eppendorf tube 
containing 5.0 p,l (5X) Reverse transcriptase buffer, 100 IU reverse transcriptase, 10 
mM dNTPS, lOmM DTTs, lOmM Pd (N) 6 and 35 IU/pl RNAguard RNase inhibitor. 
This volume was made up to 25 p i with DEPC treated water and overlayed with 
mineral oil to prevent evaporation. The tube was then placed in a thermal cycler 
(Stratagene 96 Robocycler) where the reaction was held at 37°C for 90 mins. The 
reaction was then terminated by heating to 94 °C for 20 mins when the samples were 
then used directly in the PCR reaction or, stored at -20°C for future use.
Amplification of cDNA 221,
2pl of cDNA was added to an eppendorf containing 2.5 pi (10X) Taq polymerase 
buffer, O .lpl Taq p o l y m e r a s e ^ ^ ,  2.5 p m  MgCl and 0.5mM dNTPs. Two 
oligonucleotide primers specific for the particular DNA sequence of interest were 
also added to a concentration of lpM  each. The volume was made up to 25 p i and 
overlaid with mineral oil. Amplification was carried out in a thermal cycler 
(Stratagene 96 Robocycler) where the temperatures, times, and cycle numbers of the 
denaturing, annealing and extension steps differed according to the primer used.
Agarose Gel Electrophoresis.
Horizontal submarine gel electrophoresis was used for the analysis of DNA 223.
2% (w/v) Flowgen Agarose (routine electrophoresis grade) was added to IX TAE 
buffer and heated until melting point. The solution was allowed to cool to
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approximately 60°C when ethidium bromide was added to a concentration of 
0.5pg/ml. Ethidium bromide contains a planar group which intercalates between the 
stacked bases of DNA causing the fluorescent intensity of the ethidium to increase, 
allowing the DNA product to be visualised under U.V. light.
The cooling agarose was then poured into a perspex mould and a comb placed in the 
appropriate slot. The agarose was allowed to set at room temperature when the comb 
was removed and the gel placed into an appropriate running tank with the sample 
wells towards the cathode. The gel was then covered in IX TAE, the running buffer.
DNA samples were loaded in DNA loading dye (15% (w/v) ficoll, 0.25% (w/v) 
xylene cyanol, 0.25% (w/v) bromophenol blue) and electrophoresed at 90V until the 
dye front had travelled at least halfway across the gel.
After electrophoresis, the Southern Blot technique224 was use(j t0 detect the presence 
of specific DNA sequences in the gel. In this process, DNA in the gel is denatured 
and transferred by capillary action from the gel to a nitocellulose membrane where it 
then binds (fig. 2.7).
The gel was removed from the tank and placed with the DNA uppermost against the 
Hybond-N+ nitrocellulose membrane. The Southern Blot was constructed as shown 
in figure 2.8 and care was taken to exclude air bubbles between the layers. The blot 
was left overnight before the apparatus was carefully dismantled and the membrane 
washed twice in SSC.
Probing the Membrane.
After washing, the membrane was incubated with pre-hybridisation buffer (20 ml 
(6X) SSC containing 5 mg non-fat dried milk (0.025% (w/v)) at 65°C for 2 hours. 
The membrane was then rinsed with 6 X SSC containing 0.5% SDS.
A radioactive probe was constructed by combining 5 pMol oligonucleotide 
complementary to the DNA sequence of interest, 1 pi 10X PNK buffer, 1 pl/ml T4 
PNK, 1 pi y32P ATP and 6 pi dH20. Incorporation was achieved by incubation at 
37°C for 30 mins then 65 °C for 20 mins. The labelled probe was then separated from 
the unincorporated using a Nick column.
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The membrane was then incubated overnight at 65°C in 5 mis of hybridisation buffer 
containing 10 pi of probe. The following day the probe was removed and the 
membrane was washed twice in 2 X SSC containing 0.05% SDS, then twice in 0.1 
SSC containing 0.05% SDS and finally, once in 0.1 X SSC. The membrane was then 
sealed in plastic and exposed to Fuji medical X-ray film in a Cronex Quanta Fast 
Detail Cassette autoradiography cartridge (DuPont).
2.3.5: Fixing and Staining of Colonies and Cells.
Fixation of colonies
Following the aspiration of medium, colonies were washed twice in PBS before 
fixation for 5 mins at room temperature in absolute methanol. The methanol was 
aspirated and the colonies allowed to air dry before the addition of the relevant stain.
Staining AP Positive (AP+1 Colonies.
Using glassware, Napthol AS-MX phosphate was added to dimethyl formamide to 
achieve a concentration of lOmg/ml before dilution (1: 50) in 0.1M Tris buffer. Fast 
Red salt (1 mg/ml) was dissolved in the solution and filtered before addition to the 
colony plates. After 10 mins at room temperature the stain was washed off using 
liberal amounts of dH20. Colonies expressing AP were stained a red/pink colour.
Staining of Colonies.
Colonies were visualised in culture flasks after staining with 1% (w/v) methylene 
blue in lOmM tris-borate buffer. After 30 mins at room temperature, the stain was 
washed off using liberal amounts of dH20 leaving all colonies stained a dark blue 
colour.
Light microscopy.
Colonies and cells were visualised using standard light microscopy techniques on a 
Leitz Fluorovert FS inverted microscope fitted with a 35mm camera. Photographs 
were taken on 35 mm 100 AS A tungsten transparency film and processed 
commercially.
Image analysis
Image analysis of colony areas was carried out manually on a G3 Macintosh 
computer using the image analysis software Image v. 1.6.1. Image is distributed 
freely and is downloadable from http://rsb.info.nih.gov/nih-image/
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Chapter 3: Testing Of Serum Supplements.
3.1: Introduction.
The ability to grow mammalian cells in culture has been vital for increasing our 
understanding of cell biology and biochemistry. As the growth requirements of 
normal cells in culture are not well characterised, there is almost a universal 
requirement to supplement media preparations with serum proteins 225. Serum is 
thought to be effective in supporting cultured cells because it contains a large number 
of different growth promoting factors in a physiologically balanced b le n d ^ . The 
importance of serum supplements in mammalian culture systems has been illustrated 
by experiments showing that when cells are exposed to serum free medium for a short 
time, they leave the cell cycle 226 Because serum is poorly characterised, the 
following experiments were undertaken to establish a suitable serum for use in this 
study. Both fetal calf sera (FCS) and, because of the intention to use primarily human 
cells in the study, platelet poor human plasma (PPP) were considered.
3.2: Methods.
Samples of 4 different fetal calf sera were obtained from relevant suppliers and 
compared, using markers of proliferation and osteogenic differentiation, to a serum 
currently in use and known to support osteogenic cells in culture. The sera tested 
were:
(i) Globepharm, batch number 2704.
(ii) TCS, batch number 01005.
(iii) ICN, batch number 1004011.
(iv) Imperial, batch number 42342.
The following parameters were compared:
(i) Cell numbers.
(ii) Cell proliferation.
(iii) Colony forming efficiency (Total number of colonies and AP
expressing colonies).
(iv) AP activity, a marker of osteogenic differentiation.
Bone marrow cells were obtained as described previously, from segments of rib 
removed during routine thoracic surgery from a male patient aged 59 at Frenchay 
Hospital, Bristol. The cells were seeded in standard media formulation plus lOOpM 
L-ascorbate-2-phosphate with, and without, dexamethasone (10_8M unless otherwise 
stated). The media preparation was supplemented with the appropriate test sera (10% 
v/v).
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Cells were plated at a density of 2 X 105/cm2 in T75 culture flasks (x5 / serum) and 
cultured for 21 days to assess serum effects on cell numbers. A similar plating density 
was used in 6 well plates (6 wells / serum) where cells were cultured for 21 days to 
estimate the effects on colony forming efficiency (CFE). Cells were plated in 96 well 
plates ( I X  105/well, 5 wells / serum) for both the cell proliferation and the AP 
activity assays. Estimations of both these parameters were measured at 7, 14 and 21 
days.
Cells were cultured at 37°C in a humidified atmosphere containing 5% C02. After 7 
days in culture, the non-adherent cells were removed then replenished with 
appropriate medium twice weekly thereafter. At the appropriate time point, the cells 
were harvested and parameters assessed.
Cell numbers were counted on a Coulter counter electronic cell counter. Colonies 
were fixed and stained to evaluate the total number and AP expressing, proliferation 
was measured using the MTT assay and AP activity was assessed by monitoring the 
release of p-nitrophenol from di-sodium phosphate. All these processes were carried 
out as described in Chapter 2.
All experiments were repeated at least once and data from a single representative 
experiment is shown. The distribution of the data was confirmed as normal using the 
Shapiro Wilk W test, where data was not normally distributed, a log transformation 
was used to normalise the distribution prior to test. Differences in the data were 
assessed using the one way Analysis of Variance followed by the Tukey-Kramer test 
of Honest Significant Difference (p < 0.05).
3.3: Results (Fetal Calf Sera).
3.3.1: Cell Numbers.
Cultures supplemented with the standard serum yielded the greatest number of cells 
after 21 days in culture, rank order: Standard > serum 2 > serum 1 > serum 3 > serum 
4 (fig. 3.1). The standard serum, serum 1, serum 2 and serum 3 did not differ 
significantly from each other whilst serum 4 yielded significantly lower numbers than 
the standard, 1 and 2 (p < 0.05).
When the sera were further supplemented with dexamethasone (Dx), serum 2 yielded 
the greatest number of cells, rank order: Serum 2 > 1 >standard > 4  > 3 . These 
differences were not significant.
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3.3.2: Cell Proliferation .
Cell proliferation was assessed from O.D.s.(fig. 3.2) measured at 540 nm after 7 days, 
14 days and 21 days in culture. Interpolating from the standard curve (fig. 3.3) cell 
numbers were estimated and no significant difference in the rate of proliferation was 
noted between any of the tested sera at any time point (fig. 3.4a). When further 
supplemented with Dx (fig. 3.4b), no significant inter-sera differences in proliferation 
were evident at any time point. After 21 days in culture the rank order of sera 
proliferation was: Serum 2 > standard > 3 > 1 > 4. In Dx supplemented sera, the rank 
order was: Standard > 3 > 1 > 4 > 2 .
3.3.3: Colony Numbers.
Total colony numbers and AP expressing colonies were assessed after 21 days in 
culture and the rank order of sera in the total colony category was: Standard> 1 > 4 > 
2 >3 (fig. 3.5a). Cultures containing the standard serum and serum 1 had significantly 
(p < 0.05) more colonies than cultures containing sera 2, 3, and 4. The addition of Dx 
(fig. 3.5a) to the cultures caused an overall slight increase in colony numbers for all 
groups except serum 4 where the number of colonies increased significantly.
3.3.4: AP+ Colony Numbers.
Cultures containing colonies expressing AP were ranked: serum 1 > standard > 4 > 2 
> 3 (fig. 3.5b). Serum 1 and the standard contained significantly more AP expressing 
colonies than the others. In Dx supplemented sera (fig. 3.5b), the rank order was: 
Standard > Serum 1 > 4 > 2 > 3. Again the standard and serum 1 had a significantly 
higher number of AP expressing colonies.
Expressing the number of AP colonies as a percentage of the total colony number 
(fig. 3.6) ranked: serum 1 > standard > 3 > 2 > 4. In Dx supplemented cultures, the 
standard = serum 1 > 4 > 2 > 3.
3.3.5: AP Activity.
Cultures were measured for AP activity at 7, 14 and 21 days (fig.3.7 a,b,c). No 
significant inter-serum differences in AP activity were seen at any time point whether 
+/- Dx. After 21 days in culture the rank order was: Serum 4 > 1 > 2 > 3 >  standard. 
The Dx supplemented cultures were ranked: Standard > 1 > 3 > 4  >2.
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Figure 3.1: The Effect of Different Sera on BMSC Numbers.
Unless otherwise stated: Bars represent S.E. of mean; n = 4
p < 0.05 compared to relevant control
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Figure 3.2: The Effect of Different Sera on the Proliferation of BMSC
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Figure 3.3: Standard Curve for the MTT Assay of Cell Proliferation.








Figure 3.4: The Effect of Different Sera on the Proliferation of BMSC
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Figure 3.7: The Effect of Different Sera on Alkaline Phospahatase Activity





























Human platelet poor plasma (PPP) was prepared from blood donated by healthy 
donors as previously described, and compared, using multiple parameters, to the 
standard serum currently in use and known to support proliferation and osteogenic 
differentiation. The PPP was tested for its ability to support human marrow cells in 
culture by measuring the following parameters:
(i) Cell numbers
(ii) Cell proliferation
(iii) Colony forming efficiency (Total colonies and AP expressing)
Experiment PPP 1.
To assess the ability of PPP to support BMSC in culture the initial experiment 
compared media supplemented with 10% PPP (+/- Dx) with 10% FCS (+/- Dx) in its 
ability to support proliferation. Cells were derived as previously described, from a 68 
year old female patient undergoing cardiothoracic surgery at Bristol’s Frenchay 
Hospital. Cells were randomly assigned to 1 of 4 experimental groups (table 3.1). The 
cells were seeded at a density of lx l0 4/cm2 into 3 x T75 culture flasks/experimental 
group.
Table 3.1. Experiment PPP1 Treatment Groups.
Control PPP
DMEM 90% DMEM 90%
FCS Sera 10% PPP Sera 10%
A sp2P  (100 pm) Asp 2 P (100 pm)
Control Dx PPP Dx
DMEM 90% DMEM 90%
FCS Sera 10% PPP 10%
Asp 2 P (100pm) Asp 2 P (100pm)
Dx 10'8 M Dx 10'8 M
The cells were incubated at 37°C in 5% CO2 for 7 days in a humidified atmosphere. 
At this point the media, containing non-adherent cells, was removed and the cells 
were replenished with appropriate fresh media twice weekly. The cultures were 
maintained for 3 weeks at which point the media was removed, the cells passaged and 
counted on a Coulter counter as previously described.
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3.4: Results (PPP).
3.4.1: PPP1 Cell Numbers.
Cultures supplemented with a PPP±Dx. had significantly fewer cells (p < 0.01) than 
comparable cultures supplemented with FCS±Dx (fig. 3.8).
Experiment: PPP2.
To extend the previous experiment to assess the effects of higher concentrations of 
PPP, marrow stromal cells were isolated from the rib of a 55 year old male 
undergoing cardiothoracic surgery at Bristols Frenchay hospital. Cells were randomly 
assigned to 1 of 6 experimental groups (table 3.2) to compare media supplemented 
with 10% PPP (+/- Dx), or 30% PPP(+/- Dx) with 10% FCS (+/- Dx) in their ability 
to support osteogenic proliferation/differentiation.
Table 3.2. Experiment PPP2 Treatment Groups.
Control 10% PPP 30% PPP
DMEM 90% DMEM 90% DMEM 70%
FCS Sera 10% PPP Sera 10% PPP Sera 30%
Asp 2 P (100pm) Asp 2 P (100pm) Asp2P (100pm)
Control Dx 10% PPP Dx 30% PPP Dx
DMEM 90% DMEM 90% DMEM 70%
FCS Sera 10% PPP 10% PPP 30%
Asp 2 P (100pm) Asp 2 P (100pm) Asp 2 P (100pm)
Dx 10‘8 M Dex 10-8 M Dx 10-8 M
The cells were seeded at a density of lx l0 4 /cm2 into 4 x T75 culture 
flasks/experimental group to assess cell numbers and at lx l04/cm2into 6 well plates 
(3 wells/group) to measure effects on proliferation and CFE.
The cells were incubated at 37 °C in 5% CO2 for 7 days in a humidified atmosphere. 
At this point the media, containing non-adherent cells, was removed and the cells 
were replenished with appropriate fresh media twice weekly. The cultures were 
maintained for 3 weeks at which point the media was removed, the cells to be 
assessed for cell numbers were passaged and counted on a Coulter counter as 
previously described. Colonies were visualised in the 6 well plates after staining with 
1% (w/v) methylene blue in lOmM tris-borate buffer and AP expressing colonies 
were assessed after staining with Fast Red salt, both methods as described previously.
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3.4.2: PPP 2 Cell Numbers.
Cultures supplemented with 10% and 30% PPP±Dx had significantly fewer cells (p < 
0.01) than comparable cultures supplemented with FCS±Dx, (fig. 3.9).The ratio of 
cells in the -Dx cultures; FCS:PPP(10% and 30% ) = 8 .6 . In +Dx cultures, cell ratios 
were FCS: 10% PPP = 5.9; FCS:30% PPP = 17.75.
3.4.3: PPP 2 Colony Numbers.
Cultures supplemented with 10% and 30% PPP±Dx had significantly fewer colonies 
(p < 0.01) than comparable cultures supplemented with FCS±Dx (fig. 3.10a).
Although the control Dx colony numbers are less than the control group this does not 
reflect the amount of colony coverage. Dx colonies although less in number were 
generally of a much greater size.
No AP+ colonies were formed in PPP supplemented cultures (fig. 3.10b).
Experiment: PPP3.
The previous experiment (3.4.2) was repeated using different donors for both serum 
(male 25 years) and cells (female 55 years old). PPP concentrations of 1%, 5%, 10%, 
20% and 30% (as formulated above) +/-Dx were used.
3.4.4: PPP 3 Cell Numbers.
Cultures supplemented with 10% and 30% PPP±Dx had significantly fewer cells (p < 
0.01) than comparable cultures supplemented with FCS±Dx (fig. 3.11). A negative 
correlation was seen between PPP concentration and cell numbers (fig. 3.12a,b). -Dx; 
adj. r 2 = -0.91; p < 0.01: +Dx; adj. r2 = -0.71; p < 0.05.
3.4.5: PPP 3 Colony Numbers.
PPP supplemented cultures had significantly fewer colonies, and fewer AP+ colonies 
either with or without the addition of Dx (fig. 3.13).
Experiment: PPP 4.
The above experiments were again repeated using different donors for both serum 
(male 25) and cells (male 57 years old). Additionally, the PPP was supplemented with 
EGF at 3.0 ng/ml, IGF1 at 3.0 ng/ml and PDGF(bb) at 5ng/ml (PPP+). Previous work 
has shown that in serum free systems, these components were necessary to stimulate 
cell p ro life ra tio n 2 2 7 ,2 2 8  These supplements are also reported to support the 
proliferation and osteogenic differentiation of osteogenic stem cells in vitro 
88,96,97,103,158,229.
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3.4.6: PPP 4 Cell Numbers, and Colonies
In this experiment cells, in PPP supplemented cultures almost totally failed to adhere 
and this resulted in an undetectable level of cell numbers (fig. 3.14) and colonies (fig. 
3.15).
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Figure 3.8: The Effect of Platelet Poor Human Plasma
on BMSC Numbers: Experiment I.
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Figure 3.9: The Effect of Platelet Poor Human Plasma
on BMSC Numbers: Experiment II.
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Figure 3.14: The Effect of Platelet Poor Human Plasma Supplemented
with EGF, PDGFbb and IGF-1 on the Proliferation of Human BMSC.
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Supplementation of media preparations with serum is an absolute requirement for the 
osteogenic differentiation of cells in culture. Different batches of sera reflect wide 
variations in the ability to support this process, and accordingly, choice of sera should 
be regarded as a prime importance. To maintain some consistency over a range of 
studies, it is therefore essential that a suitable batch is identified and purchased in 
sufficient volume to provide supplementation for a number of studies over several 
years.
3.5.1: Human Platelet Poor Plasma.
Samples of human PPP were obtained from a number of healthy volunteers and were 
compared using multiple parameters to assess its ability to support proliferation and 
osteogenic differentiation. It was found that at all concentrations of PPP used, either 
with or without additional supplements, PPP was consistently inferior to FCS in all 
measured parameters. It was considered that the poor performance of this supplement 
may have been related to the method of preparation. To test this, the preparation 
protocol was modified to include a final step of heat inactivation: 56°C for 30 
minutes. This modification did not significantly alter the results (not shown) and PPP 
was therefore not considered as a media supplement for this study.
The inability of PPP to support BMSC in culture was primarily related to a failure of 
cell adherence, secondary to a low proliferation rate in those that had attached.
When one considers the importance of platelet derived growth factors in bone cell 
cultures, 103,230 the inability of PPP without supplementation (PPP-) of growth 
factors, to support BMSC in culture is not surprising. Studies have shown that PDGF 
and EGF are absolute requirements for CFU-F colony development in cultures of 
BMSC229. addition of neutralising antibodies to PDGF and TGF(3 has been 
shown to cause profound inhibition of colony formation in a similar system^^l.
In the PPP 4 experiment, the failure of the added growth factors to enhance cell 
adherence might suggest that the positive effect of these factors is probably not 
related to the promotion of uncommitted non-adherent cells, it has been suggested 
that the positive effects of these agents are related to the stimulation of initial 
proliferation231 should be noted however, that in this case, none of the PPP 
supplemented cultures had any detectable numbers of cells or colonies. Comparing 
these findings with the other experiments strongly suggests that the PPP is the cause 
of the deficit and it may be that significant inter-donor differences in the ability to 
support cells in culture are to blame.
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It would be interesting to expand on these findings and investigate the effect of other 
platelet derived growth factors such as TGF(3, on this system. TGFp stimulates 
colony formation, 232 and it has been proposed that its presence in combination with 
other factors is essential for the initial proliferation of colony forming cells^^l. it is 
possible that the inclusion TGF(3, or other factors, to a PPP system might produce a 
serum capable of supporting BMSC in culture but the overall aims of this study do 
not warrant any further investigation in that direction.
However, the purpose of this study was to identify a serum capable of supporting the 
proliferation and osteogenic differentiation of BMSC in culture, and this has been 
achieved.
3.5.2: FCS.
Samples of four batches of FCS were compared using multiple parameters to assess 
their ability to support proliferation and osteogenic differentiation. Serum 1, 
Globepharm 2704, was selected as the supplement for use in this study for a number 
of reasons: (i) No other serum was significantly better at supporting cell proliferation, 
either with or without the addition of Dx. (ii) The Globepharm serum was 
significantly better than the others tested in its ability to support CFE for both total 
colonies and AP expressing colonies, either with or without the addition of Dx. (iii) 
The number of AP colonies, expressed as a percentage of the total colonies, was 
greatest in cultures supplemented with Globepharm 2704, either with or without the 
addition of Dx. (iv) AP activity was not significantly higher at any time point, in any 
other sera tested, either with or without the addition of Dx, than the Globepharm 
serum. Accordingly the Globepharm batch 2704 was acquired for use in subsequent 
in vitro studies.
3.6: Summary.
FCS and PPP were investigated using multiple parameters in order to assess their 
ability to support BMSC in culture. Cultures supplemented with FCS from different 
sources displayed a wide range of ability to support BMSC in culture. All FCS 
supplemented cultures were superior to PPP supplemented in every parameter 
measured and the most effective FCS serum (Globepharm 2704) was chosen.
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Chapter 4: The I n  V i tr o  Effects of TGFp and FGF-1 Treatments on
Bone Marrow Stromal Cells.
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4.1: Introduction.
FGFs and members of the TGF-p superfamily are important regulators of bone 
formation during development and in the adult skeleton 54,70,233-235 # Both of these 
factors are produced by cells of the osteoblast lineage in vivo and in vitro 
182,236,237 an(j are found in significant quantities in the mineralised bone 
matrix238 Numerous studies have investigated the effects of these factors on bone 
cell cultures in vitro (for TGFp review see Bonewald^39 for FGF see Hurley240). 
Most studies involving FGF have been performed only during the proliferative phase 
of osteoblast d e v e l o p m e n t a l  an(j likewise, few studies have investigated the 
temporal application of TGFP in this type of system. In the present investigation, the 
effects of FGF-2 (2.5ng/ml) and TGF-P (250pg/ml), on the proliferation and 
differentiation of osteogenic precursors in BMSC were studied
These cultures are initiated by a small number of primitive clonogenic cells (CFU-F) 
that must first become adherent before giving rise to progeny capable of proliferation 
and further differentiation. To determine the temporal effects of TGFp-1 and FGF-2 
on each of the processes (adherence, proliferation and differentiation) the factors were 
added at different stages of culture cycle and for different periods viz days 0-28 
(continuous) 0-15 (early) and 15-28 (late).
4.2: Methods.
Bone marrow cells were obtained as described previously, from segments of rib 
removed during routine thoracic surgery from a female patient aged 69 at Frenchay 
Hospital, Bristol. The cells were plated at a density of 2 x 10^/cm in 75 cm? flasks (4 
flasks/experimental group) or petri dishes (4 petris/experimental group) containing 
DMEM supplemented with 10% FCS and lOOpM ascorbate-2-phosphate (control) or 
the same medium supplemented with 2.5 ng/ml FGF-2, 250pg/ml TGFp-1 or both 
factors in combination. (Table 4.1). The medium was replenished at 7 days and 
thereafter twice weekly. After a total of 24 days in culture the following parameters 
were determined;
(1) Total colony number.
(2) Total colony area.
(3) Mean colony area.
(4) AP positive colonies.
(5) Total number of cells.
(6) Proportion of STRO-1 and AP positive cells (Flow cytometry).
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Colony number
The cultures were fixed in methanol (5 mins) and then stained with a solution of 1% 
Methylene blue /ddH20 for 30 minutes. n= 4 for each treatment.
Proportion of AP+ Colonies.
The cultures were fixed in methanol and then stained for AP activity using Napthol 
AS-MX as substrate and Fast Red as the coupling dye. Incubation with the substrate 
was at room temperature @ pH9.2. (n= 4).
Cell numbers.
Following sequential treatment with collagenase/trypsin-EDTA, cells were counted 
on a Coulter electronic particle counter model ZF. (n= 4).
Colony areas.
Colony areas were assessed manually using the image analysis software package 
Image v 1.6.1.
Flow Cytometry.
Binding of the monoclonal antibodies, STRO-1 and B4-78 (AP) was determined as 
described in Chapter 2 and according to the method of Gronthos et.al. 242
Statistical Analysis.
All experiments were repeated at least once and data from a single representative 
experiment is shown. The distribution of the data was confirmed as normal using the 
Shapiro Wilk W test, where data was not normally distributed, a log transformation 
was used to normalise the distribution prior to test. Differences in the data were 
assessed using the one way Analysis of Variance followed by the Tukey-Kramer test 
of Honest Significant Difference (p < 0.05).
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Table 4.1: Experimental Groups.
Treatment Schedule
Group Day 0 Day 15 Day 28
1. Control Control Control Control
2. Control-FGF Control FGF-2 FGF-2
3. Control-TGF Control TGF TGF
4. Control-Both Control FGF-2/TGF FGF-2/TGF
5.FGF FGF-2 FGF-2 FGF-2
6 . FGF-TGF FGF-2 TGF TGF
7. FGF-Control FGF-2 Control Control
8 . FGF-Both FGF-2 FGF-2/TGF FGF-2/TGF
9. TGF TGF TGF TGF
10. TGF-FGF TGF FGF-2 FGF-2
11. TGF-Both TGF FGF-2/TGF FGF-2/TGF
12. TGF-Control TGF Control Control
13. Both FGF-2/TGF FGF-2/TGF FGF-2/TGF
14. Both-Control FGF-2/TGF Control Control
15. Both-FGF FGF-2/TGF FGF-2 FGF-2
16. Both- TGF FGF-2/TGF TGF TGF
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Figure 4.1: Effect of Growth Factor Treatment on Total Colony Numbers.
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Each image shows 4 repeats per experimental group. Colonies are stained with methylene 
blue and appear as blue regions within the petris dishes. Images are presented in ascending 
rank order of colony numbers.
(a) Control: Cultures where no growth factors where added to the culture medium for 
entire 28 days.
(b) Both-FGF: Cultures treated with TGFp-1 and FGF-2 supplemented medium for first 15 
days then with FGF-2 only from days 15 - 28.
(c) Control-FGF: No growth factors added to the culture medium for first 15 days then 
treated with FGF-2 only from days 15 - 28.
(d) Control-TGFB: No growth factors added to the culture medium for first 15 days then 
treated with TGFp-1 only from days 15 - 28.
(e) Both-TGFB: Cultures treated with TGFp and FGF-2 supplemented medium for first 
15 days then treated with TGF-1 only from days 15 - 28.
Figure 4.2 (a-e): Effect of Treatment on Total Colony Numbers.
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(f) Both-Control: Cultures treated with TGIp-1 and FGF-2 supplemented medium for first 
15 days then treated with standard medium from days 15 - 28.
(g) Both: Cultures treated with TGFp-1 and FGF-2 supplemented medium for entire 28 
days.
(h) FGF-Control: Cultures treated with FGF-2 supplemented medium for first 15 days 
then treated with standard medium from days 15 - 28.
(i) Control-Both: No growth factors added to the culture medium for first 15 days then 
treated with FGF-2 and TGFP-1 from days 15 - 28.
(j) FGF-Both: Cultures treated with FGF-2 supplemented medium for first 15 days 
followed by FGF-2 and TGFP-1 treatment from days 15-28.
Figure 4.2 (f-i): Effect of Treatment on Total Colony Numbers
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(k) TGF-Both: Cultures treated with TGFp-1 supplemented medium for first 15 days 
followed by FGF-2 and TGFp-1 treatment from days 15-28.
(1) FGF: Cultures treated with FGF-2 supplemented medium for entire 28 days.
(m) TGF-FGF: Cultures treated with TGFp-1 supplemented medium for first 15 days 
followed by FGF-2 treatment from days 15 - 28.
(n) TGF: Cultures treated with TGip-1 supplemented medium for entire 28 days.
(o) FGF-TGF: Cultures treated with FGF supplemented medium for first 15 days 
followed by TGFp-1 treatment from days 15 - 28.
(p) TGF-Control: Cultures treated with TGip-1 supplemented medium for first 15 days 
then treated with standard medium from days 15 - 28.




Each image shows 4 repeats per experimental group. TNSAP colonies were stained 
with Fast Red TR. Colonies in these groups were sparse extremely small and are 
indicated by arrows where appropriate. In some dishes white reflective areas 
representing unstained (AP -) colonies (e.g. arrow in b) can be seen. Except for the 
control, only groups having AP +ve colonies are shown. Images are presented in 
ascending rank order of colony numbers.
(a) Control: No growth factors added to the culture medium for entire 28 days.
No AP +ve colonies were detected in this group.
(b) Both-FGF: Cultures treated with TGFp-1 and FGF-2 supplemented medium for first 
15 days then with FGF-2 only from days 15-28. Although no AP are reproduced
in this image, one small AP +ve colony was detected by naked eye examination.
(c) Control-Both: No growth factors added to the culture medium for first 15 days 
then treated with FGF-2 and TGFp-1 from days 15-28. One small AP colony was 
discovered and is illustrated (arrow).
(d) Both-TGFP: Cultures treated with TGFp-1 and FGF-2 supplemented medium for first 
15 days then treated with TGF p -1 only from days 15 - 28. Two small AP+ve colonies 
were detected and are illustrated (arrows).








(e) FGF: Cultures treated with FGF-2 supplemented medium for entire 28 days.
(f) FGF-Both: Cultures treated with FGF-2 supplemented medium for first 15 days 
followed by FGF-2 and TGFP treatment from days 15 - 28.
(g) FGF-Both: Cultures treated with FGF supplemented medium for first 15 days 
followed by TGFp treatment from days 15 -28.
(h) FGF-Control: Cultures treated with FGF-2 supplemented medium for first 15 days 
then treated with standard medium from days 15 - 28.





Figure 4.4: Effect of Treatment on Cell Number
Unless otherwise stated error bars 
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Figure 4.8: How Cytometry: Key to Populations.
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Both TGF-|3 and FGF when applied singly and continuously, increased the total 
number of colonies formed by a similar amount (figs. 4.1; 4.2). To be effective, the 
factors had to be present early. The greatest increase was seen in cultures were 
TGFp was applied early.
4.3.2: AP+ Colony Number.
In all cultures in which FGF was present early (0-7d), there was an increase in the 
number (figs. 4.3, 4.5a) and proportion of alkaline phosphatase-positive (AP+) 
colonies obtained (figs 4.5b). The effect was greatest in cultures treated with FGF for 
days 0-7 only.
4.3.3: Cell Numbers.
Treatment with FGF increased the number of cells in this system, particularly when 
applied early (fig.4.4). TGFp had no effect on cell numbers in this system.
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4.3.4: Flow Cvtometrv.
Analysis of the harvested cells by flow cytometry (fig. 4.6) using the B4-78 
monoclonal antibody revealed that the effect of FGF was associated with an increase 
in the proportion of AP+ cells in both the STRO-1+/AP+ and STRO-1-/AP+ 
subpopulations, recently it has been proposed that the levels of expression of these 
cell surface antigens provide an indication of osteogenic differentiation in cultures of 
trabecular explants243 an(j BMSC^44 (fig. 4 .8). Treatment with TGF-p alone did not 
alter the proportion of AP+ colonies, irrespective of the timing of its addition. When 
added in combination with FGF, however, the proportion of AP+ colonies was 
consistently less than that observed in the corresponding control group.
Treatment with FGF increased the proportion of cells expressing the STRO-1 antigen 
(fig. 4.6). In the experiment shown, the predominant effect was on the size of the 
STRO-1+/AP+ subpopulation, but in general, we have also found FGF to increase the 
size of the STRO-1+/AP- subpopulation245 p0r this effect to be apparent, FGF had to 
be added early (days 0-7), but not necessarily continuously (compare Ctl with FGF- 
Ctl and FGF). Treatment with TGF-p alone did not alter the size of STRO-1+/AP- 
subpopulation but did decrease the size of the dual-labelled (STRO-1+/AP+) 
subpopulation of cells. When added in combination, TGF-p tended to antagonise the 
positive effect of FGF on the expression of STRO-1. For both the STRO-1+/AP- and 
STRO-1+/AP+ subpopulations this is most evident when the effect of continuous 
treatment with both factors in combination is compared with that of FGF alone.
4.3.5: Colony Area.
Significant increases in mean and total colony area were associated with early 
treatments of FGF (fig. 4.7). TGF treatments did not significantly affect colony area.
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4.5: Conclusions.
FGF is a mitogen for human marrow stromal cells and positively influences their 
osteogenic differentiation when assessed on the basis of AP expression 245 #
Staining cultured human marrow stromal cells with the monoclonal antibodies STRO- 
1 and B4-78 (anti-bone/liver/kidney isoform AP) reveals the presence of 4 
subpopulations of cells that represent cells of the osteogenic lineage at different 
stages of differentiation (fig.4.8) 243,244 Treatment with FGF, in addition to 
increasing total cell number, selectively increases the proportion of cells present in 
the multipotential precursor (STRO-1+/AP-) and committed osteoprogenitor (STRO- 
1+/AP+) subpopulations. Other potent mitogens in this cell culture system, for 
example PDGF230 do not exhibit this same selectivity and do not alter the proportion 
of cells present in the 4 subpopulations that we have identified.
In this adult human cell culture system TGF-P did not act as a mitogen and, in 
contrast to FGF, decreased the expression of STRO-1 and the osteogenic marker AP. 
The limited effect of TGFp on the expression of STRO-1 is, in our experience, 
atypical. In general we have found that this factor is a potent inhibitor of STRO-1 
expression in this cell culture system246 jn related studies similar results have been 
obtained using the TGF-p3 isoform246 when added early (days 0 - 7), however, 
TGF-p significantly increased total colony number. This suggests that TGF-p, 
possibly through the modulation of matrix synthesis and/or integrin expression, is 
increasing the proportion of adherent cells in the initial marrow isolate. By decreasing 
the duration of exposure to TGF-p to 48 hrs and by following this treatment by 
incubation in the continuous presence of FGF, it may be possible to obtain a large 
increase in the size of the osteoprogenitor subpopulation in this cell culture system. 
This could enhance future studies on osteogenic cells in vitro. Future studies should 
address this possibility as well as determining the effects of a brief exposure to TGF- 
P on the integiins and their extracellular matrix ligands.
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Chapter 5: The/w V itr o  Effects Of Parathyroid Hormone 
Treatments On Bone Marrow Stromal Cells.
5.1: Introduction.
Parathyroid hormone is a major regulator of bone turnover in the adult skeleton. This 
84AA polypeptide acts in concert with calcitonin and 1,25 dihydroxy-vitamin D3 to 
regulate calcium homeostasis. PTH regulates minor fluctuations in extracellular 
calcium levels primarily by inhibiting calcium excretion from the kidney and by 
modulating the activity of 25-hydroxyvitamin-Dl-hydroxylase which catalyses the 
formation of 1,25 di-hydroxy-vitamin D3 from 25,hydroxy-cholecalciferol247,248 
(See fig. 1.14).
PTH exerts its effect on bone metabolism as a consequence of its function to protect 
against major reductions in extracellular calcium. At times of reduced calcium levels, 
hypersecretion of PTH from the parathyroid gland causes increased bone resorption 
and release of calcium to the extracellular se ru m 2 4 8 ,2 4 9 > Although PTH elicits 
marked increases in bone resorption, conventional wisdom does not consider this to 
be a consequence of a direct action on osteoclasts. Osteoclasts do not have receptors 
for PTH and it has been proposed that the actions of PTH on osteoclasts are 
mediated via osteoblasts 1 l^or stromal cells 1 12,118 ft js believed that the bioactivity 
of PTH resides within the NH2 terminal residues 1-34 137 ,247? epitopes within this 
region interact directly with a receptor on osteoblasts, affecting proliferation, 
differentiation and activity of the target cell 251-253 >
Interest has focused on PTH since it was demonstrated that PTH could exert anabolic 
effects on bone 137 The paradoxical effect of PTH on bone metabolism is not well 
understood and it has been suggested that different epitope binding sites in the PTH 
molecule are responsible for the disparate response to the hormone (1.3.1.).
The contradictory effects on bone turnover have also been associated with the 
temporal administration of the hormone 127, 254-256 ft ftas ajso been suggested that 
the increased bone formation associated with intermittent PTH administration is due 
to the stimulation of proliferation and differentiation of osteoprogenitor cells in the 
bone marrow 126
The effects of PTH on osteoblastic differentiation and bone formation have been 
studied both in vivo and in vitro. The in vivo anabolic effects of intermittent PTH 
administration on experimental animals 140,257,258 an(j human subjects 137,138 are 
clearly demonstrated. The in vitro effects of PTH administration on osteoblast 
differentiation however, remain contradictory, controversial and differ depending on 
the model used and the cell's differentiation status259-265 Because of the significant 
differences seen between the different culture systems and because differences are
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apparent between human and experimental animal models it was considered essential 
to use cells derived from human bone marrow cells for this investigation, which 
examines the temporal effects of treatments with hPTH(l-34) on parameters of cell 
growth and differentiation in vitro. In addition the interaction between PTH and 
dexamethasone (Dx), a synthetic derivative of the glucocorticoid cortisol, on the same 
parameters was investigated. Glucocorticoids are known to increase the proliferation 
and/or osteogenic differentiation of marrow stromal cells derived from certain 
species including rats and humans 178,181,266-268 Importantly, Dx is reputed to 
augment the ability of marrow stromal cells to respond to PT H ^^possibly  by 
enhancing ligand binding to the receptor or increasing PTH receptor expression 269
A pilot experiment was undertaken to assess the dose response relationship of PTH 
treatment on the proliferation and osteogenic differentiation of bone marrow stromal 
cells. Cell morphology, cell numbers, surface expression of STRO-1 and AP, CFE 
and colonies expressing AP, an early indicator of osteogenic differentiation in 
marrow stromal cultures 180, were assessed. The anabolic effect of PTH is thought to 
be mediated via the cAMP/PKC pathway 109,125,142,144,161,270^ an(j as tfhs 
response is accepted as a characteristic of the osteogenic p h e n o t y p e ^  1, cAMP 
response to the PTH treatments was also measured.
5.2: Methods.
Bone marrow cells were obtained as described previously, from segments of rib 
removed from a female patient aged 68, during routine thoracic surgery at Frenchay 
Hospital, Bristol. Cells were plated at a density of 2 x 105/cm 2 in standard media 
formulation plus IOOjiM ascorbate-2-phosphate supplemented with hPTH(l-34) at 
0.1 nM, l.OnM, lOnM and lOOnM, in the presence and absence of Dx. To assess the 
effects of PTH on cell numbers and for analysis of surface STRO-1 and AP 
expression by flow cytometry, cells were seeded in T75 culture flasks 
(x4/treatment/analysis) and cultured for 21 days. To measure intracellular cAMP 
levels, cells were plated in 6 well plates (xl plate/treatment), and to estimate the 
effects on colony forming efficiency (CFE), and colony area, cells were seeded in 
petri dishes (4 petris/treatment) and cultured for 21 days.
Cells were cultured at 37°C in a humidified atmosphere containing 5% C02. After 7 
days in culture, the non-adherent cells were removed then replenished with the 
appropriate medium twice weekly thereafter. At the appropriate time point, the cells 
were harvested and parameters assessed according to methods described in Chapter 2.
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Briefly, cells were counted on a Coulter counter electronic cell counter. Colonies 
were fixed and stained with methylene blue to evaluate the total number and Fast Red 
TR to estimate the number expressing AP. cAMP values were calculated according to 
instructions supplied with the Biotrak cAMP enzymeimmunoassay system and 
normalised to fMol cAMP/mg protein using the Bio-Rad DC protein assay. Flow 
cytometry was carried out according to the methods of Simmons208t image analysis 
(NIH Image vl.61) was used to manually measure the area of the colonies.
All experiments were repeated at least once and data from a single representative 
experiment is shown. The distribution of the data was confirmed as normal using the 
Shapiro Wilk W test, where data was not normally distributed, a log transformation 
was used to normalise the distribution prior to test. Differences in the data were 
assessed using the one way Analysis of Variance followed by the Tukey-Kramer test 
of Honest Significant Difference (p < 0.05).
5.3: Results.
5.3.1: Cell Morphology.
The presence of PTH at concentrations of lOnM and lOOnM affected cell 
morphology. In control cultures, cells were fibroblastic in shape (fig. 5.1a) This 
differed from the more elongated fibroblastic as well as the cuboidal morphology 
seen in the PTH treated cultures (fig 5.1c) Treatment with Dx resulted in a 
morphological transformation of the cells from fibroblastic (fig 5.1a) to elongated 
fibroblastic (fig. 5.1b). Treatment with PTH and Dx resulted in cultures with 
elongated fibroblastic and cuboidal morphology (fig. 5 .Id) similar to that seen in the 
PTH treatments but with an apparent increase in density.
5.3.2: cAMP Response.
Treatment with PTH > lOnM significantly increased the intracellular cAMP levels 
compared to the control, (fig. 5.2.) Cultures treated with O.lnM PTH had similar 
levels of intracellular cAMP as the control, l.OnM treated cells had a small 
insignificant reduction in cAMP concentration.
In cultures where PTH was added in combination with Dx, treatment with PTH at all 
doses tended to increase the levels of intracellular cAMP. Only at doses > lOnM 
however, did the increase attain statistical significance.
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5.3.3: Cell Numbers.
Treatment with lOOnM PTH increased cell number significantly (fig. 5.3), 
irrespective of the absence or presence of Dx. The combined effect of lOOnM PTH + 
Dx was greater than that of either factor alone (p < 0.05).
5.3.4: Total Colony Numbers.
Treatment with PTH at lOnM increased the colony forming efficiency of marrow cell 
suspensions (p < 0.05) (fig. 5.4a; 5.5a).
Treatment with Dx alone tended to increase the colony forming efficiency of marrow 
cell suspensions (fig.5.4b; 5.5a). When added in combination with lOOnM PTH the 




The mean area of the colonies formed in cultures treated with PTH or Dx was similar 
to that of the control cultures. This same parameter was increased significantly 
however in cultures treated with lOOnM PTH and Dx in combination (fig.5.6a)
Total area.
Using a single representative plate from each treatment group, the total colony area 
was found to be notably increased in the lOnM treatment compared to the control, 
when PTH was administered alone (fig. 5.6b).
In cultures where PTH was combined with Dx, a considerable increase in total area 
was seen in the lOOnM Dx cultures, ~ x4 compared to control (fig. 5.6b).
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5.3.6: AP+ Colonies.
Treatment with PTH or Dx did not alter the number of AP + colonies (figs. 5.4c,d; 
5.5b).
Treatment with Dx and lOOnM PTH in combination however induced a significant 
increase in the number of AP+ colonies.
5.3.7: AP+ Colony Area.
Mean area.
PTH treatment was related to insignificant increases in mean colony area (fig. 5.7a). 
whereas treatment with PTH+Dx had no general effect.
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Total area.
Cultures treated with PTH had greater total colony areas than the control although the 
differences between treatments was comparatively small (fig. 5.7b).
The Dx supplemented cultures showed similar colony areas except in the case of the 
lOOnM Dx treatment which was ~ x 20 greater than the next highest treatment (fig. 
5.7b and fig. 5.4c,d).
5.3.8: Percentage of Colonies Expressing AP.
In the presence of PTH, Dx or both factors in combination, there was a general trend 
for the percentage of AP+ colonies formed to be increased (fig. 5.8a). In every case 
however, the observed increase did not attain statistical significance
The number of AP+ colonies strongly correlated with the total number of colonies, 
adj. r 2 = 0.82, (p < 0.001) (fig. 5.8b)
5.3.9: Flow Cytometry.
In cultures treated with PTH only, the sub-population distribution in the 0.1 nM, 
l.OnM and lOnM treatments did not differ dramatically from the control (fig. 5.9b-e; 
simplified in fig. 5.11a). In the lOOnM treated cultures (fig. 5.9f; 5.11a), only 15% of 
cells were present in the -/- population suggesting a shift in the cell distribution 
towards the sub-populations associated with the osteogenic pathway.
In the PTH/Dx treated cultures, the sub-population distributions in the O.lnM Dx and 
l.OnM Dx cultures were similar to the control (5.10b-d; 5.1 lb) These PTH/Dx treated 
groups differed from the control only in that they had a modest shift in the sub­
population distribution from the -/- towards the osteogenic phenotype. The lOnM Dx 
treatment differed noticeably from the control with marked increases in the STRO- 
1+/AP-, and STRO-1+/AP+ sub-population (5.10e; 5.11b). Additionally, the STRO- 
1-/AP+ population in the lOnM Dx cultures was much less than the control value. 
The lOOnM Dx cultures when compared to the control revealed a large shift in the 
sub-populations towards the osteogenic phenotype (5.10f; 5.11b).
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Figure 5.1 Photomicrographs (x 400 orig. mag.) at 21 days culture,
(a) Control; (b) Control Dx; (c) PTH (lOnM); (d) PTH (lOnM) Dx
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Figure 5. 3: Effect of PTH±Dx Treatment on Cell Numbers.
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Figure 5.4: Photographs showing colony coverage at 21 days 
in response to (a) PTH; (b) PTH Dx.
AP+ colony coverage at 21 days 
in response to (c) PTH; (d) PTH Dx.
Figure 5. 4 (a-d:) Effect of PTH Treatment on Colony Numbers
and AP+ Colony Numbers.
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Figure 5. 8: (a) Effect of PTH Treatment on the % of Colonies Expressing AP;
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Figure 5. 9 (a-f): Effect of PTH Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 5. 10 (a-f): Effect of PTH Dx Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
Isotype matched















Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FTTC) 
on the x  -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 
appeared within the lower left quadrant (a).
Figure 5. 11: Effect of PTH±Dx Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Relative proportions of sub-populations of cells labelled with the STRO-1 
and AP antibodies. Block areas represent relative sub-population sizes, 
numbers associated with blocks are percentage of cells (to nearest percent). 
Arrows represent the direction of increasing osteogenic differentiation.
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5.4: Discussion.
Treatment with hPTH ( 1 - 3 4 )  in the range 1 0 - lOOnM caused early changes in bone 
marrow stromal cell (BMSC) morphology. Previous studies have demonstrated that 
treatment with PTH ( 1 - 3 4 )  or its analogues, produced morphological changes in 
osteoblast-like c e l l s 2 7 2 , 2 7 3  an(j osteoblasts, both in v i t r o ^ 7 4  and in v i v o  16. These 
studies described changes at an ultrastructural level, in the nuclear matrix and 
cytoplasm, so it seems unlikely that changes of this magnitude would be visible at the 
magnification shown. Furthermore, as BMSC cultures are heterogeneous, with 
osteoblasts and their precursors representing a minority constituent at this stage of 
culture 1 7 8 , 2 7 5 ? such morphological changes would therefore not lead to the overall 
change in morphology seen in these groups.
PTH treatments have been shown to increase proliferation in osteoblast-like cell 
1^68^52,276^ trabecular bone-derived cells of h u m a n ^ 5 9  an(j rat origin 1 4 4 , 2 7 7  a s  
well as increase the proliferation of osteoprogenitor cells in cultures of rat bone 
marrow 126 It therefore seems feasible that the change in cell morphology associated 
with PTH treatments could be related to an increase in cell density caused by 
increased proliferation. However, the PTH associated changes in cell numbers seen 
this experiment were not dramatic (maximum of 1 .7 5  and 1 . 6 6  fold increase with 
PTH±Dx) and therefore makes this an unlikely explanation.
Inter-treatment variations in morphology could be due to a disparity in differentiation 
stage, PTH has been shown to stimulate osteogenic differentiation in trabecular 
explants 120, ex vivo marrow cultures 126 an(j jn osteoblast-like ce lls^O  an(j ^  
follows that the PTH treated cultures may have advanced further along the 
differentiation pathway than the untreated controls, and reflect this maturation with a 
change in morphology. However, given that the osteogenic influence of PTH is 
directed against the osteogenic sub-population and that this population is relatively 
small, then one would not expect to see the global effect on cell morphology that was 
seen in these cultures
cAMP has been shown to alter the morphology in a wide range of cell types in vitro 
278-281 ancj jn this system an intracellular cAMP response to PTH treatments may be 
responsible for differences in cell morphology. This concept is supported in part, by 
the observation that the changes in cell morphology among the PTH treatments were 
only seen in the lOnM and lOOnM cultures, and these were the only groups which 
showed an increase in intra-cellular cAMP in response to hPTH. When cells were 
treated with hPTH accompanied with Dx, the greatest change in morphology was
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seen in the 10nM±Dx and 100nM±Dx treatments and these were the only groups 
where the cAMP response to hPTH was significantly higher than the control. The 
importance of this change in cell morphology is underlined by work which 
demonstrates that PTH alteration of osteoblast membrane, cytoskeletal and 
nucleoskeletal proteins may direct PTH signalling pathways to target genes and 
modulate osteoblast gene expression274
Treatment with hPTH at lOOnM caused a significant increase in cell numbers. A 
similar pattern was seen in cultures which were additionally supplemented with Dx 
with the exception that the increase at both the lOnM and lOOnM doses reached 
significance. A number of mechanisms could be responsible for this increase in cell 
numbers. PTH has been previously shown to increase cell proliferation in a variety of 
osteogenic in vitro systems 126,144,252,259,276,277,282# a  number of studies 
suggest that the PTH associated increase is mediated via the cAMP/PKA pathway 
144,277,283-285 the overall evidence is contradictory, with others reporting that 
PTH stimulates proliferation by a mechanism not using the cAMP/PKA pathway
286,287 An examination of the relationship between intra-cellular concentrations of
2
cAMP and cell numbers in this study reveals a correlation of adj. r = 0.38; p = 0.03. 
(least squares regression analysis, Anova; (not shown)). This equates to a moderate 
but statistically significant association between intracellular cAMP levels and cell 
numbers and therefore suggests that other pathways may act in association with 
cAMP/PKA to bring about change. This concept is supported by reports that the 
cAMP/PKA pathway acts in concert with the PKC paths to effect increases in 
proliferation 144.
Recent reports suggest that the increase in cell numbers associated with PTH 
treatment is not due to an increase in proliferation but caused by a reduction in 
osteoblast apoptosis288 It is proposed that PTH acts directly on osteoblasts and 
initiates the cAMP/PKA pathway which then interferes with some death pathways. 
As mentioned above, the level of association seen in this study between cell numbers 
and intracellular cAMP suggests the co-involvement of other signal pathways in the 
PTH associated increase in cell numbers
An increase in cell numbers would also result from any mechanism which enhanced 
the capability of the normally non-adherent BMSC population to convert to the 
adherent cell type. It has been proposed that these non-adherent cells represent a 
differentiation stage which precedes that of the adherent cells 289 There is evidence 
that some bone anabolic agents, which include PTH, enhance both bone cell numbers 
and bone formation by recruiting osteoblast precursors present in the non-adherent
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population and promoting them to the more differentiated adherent population289- 
291. The involvement of cAMP is also implicated in this process, 290 so  ̂ can  be 
seen that activation of the cAMP/PKA pathway is an important component in the 
anabolic response associated with PTH administration.
The evidence provided by this experiment, and that of work already discussed, is not 
sufficient to define a precise mechanism by which PTH treated cultures have 
increased cell numbers. It is likely that increased cell proliferation, cell adherence and 
a reduction in apoptosis all act in concert to bring about a net gain, but an elucidation 
of this effect will require the study of other parameters.
Treatment with hPTH in the O.lnM-100nM±Dx range increased the numbers of 
colonies compared to the control, and the increase was statistically significant in 
cultures treated with lOnM and lOOnM Dx. Comparing the ±Dx treatments revealed a 
trend where the application of Dx increased the CFE. This finding is generally in 
accordance with earlier work which demonstrated that the administration of Dx to 
human culture systems increases the proportion of cells with osteogenic potential 
292,293 an(j upregulates colony forming efficiency 1^0 The reason for the Dx 
associated increase in CFE is largely unknown but is thought to be linked to its effect 
on primary cell adhesion 1^0
Previous work on the effects of PTH on colony forming efficiency in cells derived 
from mouse marrow revealed no difference in cultures treated with PTH294 This 
was in contrast to the findings from a rat model where PTH increased colony forming 
efficiency by 25%289. In an ex-vivo model, cultures of marrow explants from rats 
treated with PTH yielded a greater number of colonies (320%) than the vehicle
treated controls 126
In this study, the increase in the number of colonies in cultures treated with PTH 
could be due to an overall increase in cell numbers. Plotting cell numbers against 
colony number, least squares regression analysis reveals a correlation coefficient of 
adj.r2 = 0.69 (p = 0.002). This suggests that the number of cells in a culture is an 
important and highly significant factor which influences the process of colony 
formation. This could simply be because any increase in the number of cells will 
concomitantly lead to an increase in the number of cells which have the ability to 
form colonies. If the increased cell numbers are due to a PTH induced increase in 
proliferation then it follows that colonies in the PTH treated cultures would be larger. 
An examination of mean colony areas in groups where 0-lOOnM PTH was applied,
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revealed no real inter-treatment differences. The overall colony coverage per
2
treatment group was a function of the number of colonies (adj.r = 0.80; p = 0.02)
2
rather than the mean area of the colonies (adj.r = -0.31; p = 0.86). This suggests that 
in these groups, the overall increase in cell numbers is due to a mechanism other than 
increased proliferation. As discussed above, agonists which increase intracellular 
levels of cAMP have been shown to induce the transition of the normally non­
adherent BMSC to become adherent289-291 thereby increasing the number of cells in 
culture. In this study, the increase in the number of cells and colonies in PTH treated 
groups could be explained by this model.
Where PTH was applied with Dx, no real difference was seen in mean colony areas in 
the 0.1-10nM PTH Dx range. A significant increase in area was seen in the lOOnM 
Dx cultures. The overall colony coverage per treatment group was more closely 
related to the mean area of the colonies (adj.r2 = 0.86* ; p = 0.01) rather than the total 
number of colonies (adj.r^ = 0.34*; p = 0.17) suggesting the influence of proliferation 
on cell numbers was greater in cultures supplemented with Dx. On closer analysis it 
can be seen that this is probably not the case. Only in the lOOnM Dx cultures was 
there any evidence of greater proliferation in the form of increased mean colony area, 
it was however of sufficient magnitude to skew the result in that direction.
In cultures further supplemented with Dx the increase in colony number in the range 
0.1-10nM PTH is likely due to the transition of the normally non-adherent BMSC to 
adherent and, in the lOOnM Dx group it is likely that this mechanism is augmented by 
a concomitant increase in proliferation.
Expression of AP is an early and widely accepted sign that a cell has initiated a 
program of osteogenic differentiation 295 The number of colonies expressing AP was 
increased in cultures treated with PTH±Dx and this increase is consistent with an 
enhancement of osteogenic differentiation 180. However, this increase only reached 
significance in the presence of lOOnM PTH+Dx. The percentage of total colonies 
which expressed AP varied widely between the treatment groups although none of 
these differences were significant. This could be due to the small numbers of AP+ 
colonies present. The number of AP+ colonies per treatment group was closely 
correlated of the total number of colonies (adj.r2 = 0.76; p <0.001) and this 
information along with the percentage data provides evidence that the increase in 
AP+ colonies and osteogenic enhancement may not be a direct result of PTH 
administration per se but could be a function of increased colony forming efficiency.
* Plotting the natural log of the data to normalise the distribution.
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An estimate of the differentiation status of the cultures was achieved by analysis of 
the expression of cell surface antigens STRO-1 and AP. Recently it has been 
proposed that the levels of expression of these cell surface antigens provide an 
indication of osteogenic differentiation in cultures of trabecular explants^43 an(j 
BMSC244.
In cultures treated with O.lnM and l.OnM PTH the percentage of cells in the STRO-1 
-/AP- population were similar to that of the control. This group is the most 
heterogeneous of the 4 sub-types and is thought to contain very early uncommitted 
cells of the osteoblast lineage, as well as late stage cells - osteocytes/lining cells 244 
This suggests at these doses, PTH does not promote the progression of the early 
uncommitted cells of the STRO-1 -/AP- population to a more differentiated state. 
Analysis of the sub-populations representative of the more differentiated phenotypes 
failed to reveal any obvious pattern associated with PTH treatment. In the O.lnM 
treatments, the percentage of cells in the STRO-1/AP+ population, representing the 
most differentiated sub-type, was almost double that seen in the control group, 
however, this percentage returned to control levels in the 1 .OnM cultures. Considering 
this data along with the cAMP, cell number and colony data suggests that treatment 
with PTH at O.lnM and l.OnM concentrations has little or no effect in this system.
In the lOnM and lOOnM cultures there was a reduction in the proportion of cells in 
the STRO-1 -/AP- population. This may suggest that these concentrations of PTH 
promote the early uncommitted cells of the STRO-1 -/AP- population to a more 
differentiated state. In the lOnM treatment the proportions of cells tended to be evenly 
spread among the population sub-types. In the lOOnM cultures however, a large shift, 
compared to any of the other groups was seen in the distribution of populations. In 
this group 85% of cells were present in the osteogenic differentiation pathway but 
their distribution was strongly skewed towards the less differentiated state. In this 
group only 3% of cells were present in the STRO-1-/AP+ population. This may 
indicate that PTH enhances the recruitment of early uncommitted cells to the 
osteogenic differentiation pathway but inhibits their progress when they reach a 
certain, as yet unidentified, differentiation stage.
In cultures where PTH was supplemented with Dx, all PTH treatments in the range 
0.1-lOOnM were associated with an increase in the proportion of cells present in the 
committed pathway. In the O.lnM and l.OnM cultures, the distribution of cells among 
the committed sub-populations was similar to that seen in the control group and this 
reinforces the earlier supposition that at these concentrations PTH exerts a negligible 
or zero effect. In the lOnM culture the distribution was very similar to that of the
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lOOnM -Dx. In the lOOnM Dx group, 90% of cells were present in the committed 
pathway and in contrast to the comparable -Dx treatment, the distribution was 
strongly skewed towards the more differentiated state. In this system increased colony 
area provided evidence of increased proliferation and that may account for increased 
proportions of cells with osteogenic potential. The presence of Dx would accelerate 
their progress along the differentiation pathway.
5.5: Summary.
PTH treatment: PTH at doses > lOnM does not affect parameters of growth and 
differentiation in this cell culture system. Concentrations of lOnM and lOOnM 
increase cell numbers most likely by enhancing cell adhesion rather than increasing 
proliferation as evidenced by increased colony numbers but not colony area. 
Osteogenic differentiation is not enhanced by lOnM and lOOnM PTH as evidenced by 
the proportion of AP+ colonies and STRO-1, AP cell surface expression. Increased 
intracellular cAMP is likely to be an important mediator of the actions of PTH.
PTH+Dx treatment: Changes similar to those listed above were noted with the 
following exceptions; lOOnM PTH+Dx synergistically enhanced cell number by 
increasing proliferation and adhesion (colony areas and numbers increased) and also 
increased osteogenic differentiation (AP+ colonies and AP+ cells increased). 
Osteogenic differentiation was increased compared to comparable -Dx cultures. 
(Increased AP+ colonies probably due to presence of Dx).
If PTH exerts a significant influence on BMSC via its effects on early (uncommitted) 
cell adhesion/recruitment then the timing of PTH treatment is an important parameter 
and may effect cell responses to treatment. This concept is supported by evidence that 
PTH exerts dissimilar effects which are treatment time dependant 160 Suggestions 
that the PTH target cell is an immature osteoblast294 or preosteoblast 296 acjd further 
weight to this argument.
To investigate this, subsequent experiments will add a temporal aspect to the 
administration of PTH with comparisons made between early, late and continuous 
treatments. Experiments will also be extended to investigate possible mechanisms for 
the interaction between PTH and dexamethasone on BMSC
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Chapter 6: T h e  I n  V i tr o  Effects Of Delayed Parathyroid Hormone 
Treatments On Bone Marrow Stromal Cells.
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6.1: Introduction.
The PTH dose response experiments demonstrated that PTH at concentrations of 
lOnM and lOOnM are capable of increasing the number of colonies, cells and, when 
applied with Dx, AP+ colonies in cultures of human BMSC.
On the basis of these findings it was postulated that PTH targets early (uncommitted) 
cells and affects the adhesion and/or recruitment to the osteogenic lineage in cultures 
of BMSC. To test this hypothesis, experiments were performed in which PTH was 
applied from the start of the culture period (continuous), and after 48 hours had 
elapsed (delayed). In both instances, treatment was then continued until the end of the 
culture period. The rationale for this approach is, that in the delayed experiment, cells 
in the non-adherent fraction are removed prior to the application of PTH thereby 
depleting the cultures of the putative target cell population (pre-CFU-F).
If, as has been previously suggested however, the target cells are the immature 
osteoblast and/or preosteoblast294,296 then the delayed treatment will bypass the 
very early differentiation stages of these cell types, this delayed addition of PTH will 
have effects on parameters of growth and differentiation distinguishable from those 
observed in the continuous group.
6.2: Materials and Methods.
Bone marrow cells were obtained as described previously, from segments of rib 
removed from a patient aged 31 of unknown sex during routine thoracic surgery at 
Frenchay Hospital, Bristol. Cells were plated at a density of 2 x 105/cm2 in standard 
media formulation plus 100|iM ascorbate-2-phosphate supplemented with hPTH(l- 
34) at lOnM and lOOnM, in the presence and absence of Dx.
To assess the effects of PTH on cell numbers and for analysis of the surface 
expression of STRO-1 and AP by flow cytometry, cells were seeded in T75 culture 
flasks (x4/treatment/analysis) and cultured for 21 days. To estimate the effects on 
colony forming efficiency (CFE), colony area and optical density, cells were seeded 
in petri dishes (4 petris/treatment) and cultured for 21 days.
Cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2. After 48 
hours in culture, the non-adherent cells were removed, cultures were replenished with 
appropriate medium and fed twice weekly thereafter. At the appropriate time point,
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the cells were harvested and parameters assessed according to methods described in 
Chapter 2.
All experiments were repeated at least once and data from a single representative 
experiment is shown. The distribution of the data was confirmed as normal using the 
Shapiro Wilk W test, where data was not normally distributed, a log transformation 
was used to normalise the distribution prior to test. Differences in the data were 
assessed using the one way Analysis of Variance followed by the Tukey-Kramer test 
of Honest Significant Difference (p < 0.05).
6.3: Results.
6.3.1: Cell Morphology.
The continuous presence of PTH at concentrations of lOnM and lOOnM affected the 
morphology of the cells in a similar manner to that seen in PTH experiment 1 (not 
shown). Where PTH was applied late, no obvious change was seen in cell 
morphology. Dx produced changes as previously seen in PTH experiment 1.
6.3.2: Cell Numbers.
Where PTH was applied without Dx, no effect was seen with either continuous or 
delayed treatments (fig. 6.1a,b). The addition of Dx to the system caused a significant 
increase of cell numbers in the continuously treated lOOnM cultures and a significant 
decrease in the delayed treated lOnM cultures (p < 0.05).
Comparing the continuous to the late treatments, the number of cells was less in all 
the late cultures. This reduction was significant in the lOOnM, lOnM Dx and the 
lOOnM Dx cultures (p < 0.05).
6.3.3: Total Number of Colonies.
Continuous treatment with PTH alone increased the total number of colonies, and this 
increase was significant in both the lOnM and lOOnM cultures (figs. 6.2a; 6.3a). 
Cultures treated with PTH and Dx showed a significant decrease in the number of 
colonies in the lOnM Dx treatments and a small insignificant increase in the lOOnM 
Dx treatments (figs. 6.2b; 6.3a)
When PTH treatment was delayed, the number of colonies was considerably 
decreased in both the lOnM and lOOnM cultures (fig. 6.2c; 6.3b).
In the PTH+Dx cultures a similar significant decrease was seen in the lOnM and 
lOOnM Dx treatments (figs. 6.2d; 6.3b)
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6.3.4: Mean Colony Area.
Treatment with PTH had no significant effect on mean colony area under any 
condition (fig. 6.4a,b).
6.3.5: Total Colony Area.
Using a single representative plate from each treatment group, where PTH was 
applied continuously, the total colony area did not differ greatly between the control 
and the treatment groups (fig. 6.5a). In cultures where PTH was combined with Dx, a 
considerable decrease in total area was seen in the lOnM Dx cultures, * x 0.5 
compared to control. A slight decrease was seen in the lOOnM Dx cultures (fig. 6.5a).
Irrespective of the presence of absence of Dx, when PTH treatment was delayed, the 
total colony areas were considerably reduced in a dose dependent manner, compared 
to the control (fig. 6.5b).
6.3.6: AP+ Colonies.
Continuous treatment with PTH at both lOnM and lOOnM caused a significant 
increase (p < 0.05) in the number of colonies expressing AP compared to the control 
(figs. 6.6a; 6.7a). PTH further supplemented with Dx significantly increased (p < 
0.05) the number of colonies expressing AP in the lOOnM Dx treatment (figs. 6.6b; 
6.7a).
Delayed treatment with PTH at the lOOnM level caused a significant reduction (p < 
0.05) in the number of AP+ colonies (figs. 6.6c; 6.7b).
In Dx supplemented cultures, treatment with PTH at both lOnM and lOOnM caused 
significant decreases (p < 0.05) in the number of AP+ colonies (figs. 6.6d; 6.7b).
Comparing early and late treatments revealed that the number of AP+ colonies was 
lower in all the late PTH treatments, and significantly so in the lOOnM, lOnM Dx and 
lOOnM Dx cultures (p < 0.05) (figs. 6.6c,d; 6.7a,b).
6.3.7: AP+ Colony Mean Area.
Treatment with PTH±Dx, irrespective of conditions, had no significant effect on the 
mean areas of AP+ colonies (figs. 6.8a,b).
6.3.8: AP+ Colony Total Area.
Cultures treated continuously with PTH had greater colony total areas than the control 
(fig. 6.9a). In Dx supplemented cultures, the lOnM treatments had a reduction in
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colony area while the lOOnM treatments had a considerable increase in area (fig. 
6.9a)
Irrespective of the presence of absence of Dx, when PTH treatment was delayed, the 
total colony areas were considerably reduced in a dose dependent manner, compared 
to the control (figs. 6.9b).
6.3.9: Percentage of Colonies Expressing AP.
Continuous or delayed treatment with PTH±Dx had no effect on the percentage of 
colonies expressing AP (fig. 6.10a,b). In the continuously treated, the number of AP+ 
colonies correlated with the total number of colonies, adj. r2 = 0.61, (p < 0.05) In 
the delayed treated, the number of AP+ colonies correlated with the total number of 
colonies, adj. r 2 = 0.70, (p < 0.05)
Comparison between the continuous and the late treatments, revealed no significant 
differences in the percentage of AP+ colonies (figs. 6.10a,b).
6.3.10: Flow Cvtometrv.
In cultures continuously treated with lOnM PTH, the sub-population distributions 
were markedly different from the control (fig. 6.11c,d; simplified in fig. 6.15a). The 
percentage of cells in lOnM treatment was either = double or = half of the comparable 
control sub-population. Control:Treatment; STRO-1-/AP-, 24:51; STRO-1+/AP-, 
45:18; STRO-l+:AP+, 21:11; STRO-1-/AP+, 10:20. In the lOOnM cultures the 
differences from the control were not as marked as that seen in the lOnM treatments 
(figs. 6.11b,d; 6.15a); STRO-1-/AP-, 29; STRO-1+/AP-, 31; STRO-l+:AP+, 24; 
STRO-1 -/AP+, 16. Compared to the controls, the PTH treated cultures had a higher 
percentage of cells in the STRO-1-/AP+ and STRO-1-/AP-populations.
In the continuous PTH Dx treated cultures, the sub-population distributions in the 
PTH treated cultures were markedly shifted towards the osteogenic phenotype (fig. 
6.12c,d; 6.15b). Compared to the controls, the PTH Dx treated cultures had a higher 
percentage of cells in the STRO-1-/AP+ and a lower percentage in the STRO-1-/AP- 
populations.
Where PTH treatment was delayed, the overall sub-population distributions were 
notably different from the control (fig. 6.13b-d; 6.16a). In both the lOnM and lOOnM 
cultures, the distribution of cells was skewed towards the less differentiated 
phenotypes. In the STRO-1-/AP+ population, the percentage of cells in the PTH 
groups was considerably lower than the control.
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In these cultures, when PTH was supplemented with Dx, a population pattern similar 
to that seen in the -Dx cultures was observed (fig. 6.14b-d; 6.16b). The Dx 
supplemented system differed mainly in the proportion of cells present in the lOOnM 
STRO-1-/AP- and STRO-1+/AP- populations.
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Figure 6.1: Effect of PTH±Dx Treatment on Cell Number,
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Figure 6.2: Photographs showing colony coverage at 21 days
in response to continuous treatment with (a) PTH; (b) PTH Dx. 
and delayed treatment with (c) PTH; (d) PTH Dx.
Figure 6.2: Effect of PTH±Dx Treatment on Colony Number,
















Figure 6.3: Effect of FTH±Dx Treatment on Colony Number,





































































































Figure 6.4: Effect of PTH Treatment on Mean Colony Area,





















































































Figure 6.5: Effect of PTH Treatment on Total Colony Area,
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Figure 6.6: Photographs showing AP+ colony coverage at 21 days
in response to continuous treatment with (a) PTH; (b) PTH Dx. 
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Figure 6.8: Effect of PTH±Dx Treatment on AP+ Mean Colony Area,
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Figure 6.9: Effect of PTH±Dx Treatment on AP+ Total Colony Area,
(a) Continuous and (b) Delayed.
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Figure 6.10: Effect of PTH Treatment on Percentage of Colonies Expressing AP,












































































Figure 6.11 (a-d): Effect of Continuous PTH Treatment on the
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 6.12 (a-d): Effect of Continuous PTH Dx Treatment on the
Co-Expression of STRO-1 and AP Antigens as Assessed by How Cytometry.
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the x  -axis and red fluorescence(R-PE) on the y-axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 6.13 (a-d): Effect of Delayed PTH Treatment on the
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 6.14 (a-d): Effect of Delayed PTH Dx Treatment on the
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 
appeared within the lower left quadrant (a).
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Figure 6. 15: Effect of Continuous (a) PTH (b) PTH Dx Treatment on the
Co-Expression of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Relative proportions of sub-populations of cells labelled with the STRO-1 
and AP antibodies. Block areas represent relative sub-population sizes, 
numbers associated with blocks are percentage of cells (to nearest percent). 
Arrows represent the direction of increasing osteogenic differentiation.
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Figure 6.16: Effect of the Delayed Treatment of (a) PTH (b) PTH Dx on the
Co-Expression of STRO-1 and AP Antigens as Assessed by How Cytometry.
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Relative proportions of sub-populations of cells labelled with the STRO-1 
and AP antibodies. Block areas represent relative sub-population sizes, 
numbers associated with blocks are percentage of cells (to nearest percent). 
Arrows represent the direction of increasing osteogenic differentiation.
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6.4: Discussion.
Continuous treatment with PTH at IOnM and lOOnM concentrations caused early 
changes in bone marrow stromal cell morphology similar to that seen in the initial 
PTH experiment. However when PTH was applied late, no meaningful difference in 
cell morphology was noted between the late treatments and the control. This suggests 
that PTH must be in the culture system early in order to affect cell morphology. Late 
PTH treatments were applied after the non-adherent cell population had been 
removed and the finding of this experiment lends support to the notion that the 
primary target cell of PTH is the uncommitted/non-adherent cell289.
The results of this experiment also support the suggestion that the target cell may be 
the immature osteoblast 294  0r pre-o steob last296  In the present system, the late 
application of PTH allows such cells to progress to a more advanced stage of 
differentiation before being challenged by PTH. This therefore reduces the number of 
potential targets for PTH in the culture and consequently reduces the effect of the 
treatment.
Treatment with PTH at IOnM and lOOnM concentrations caused no significant 
change in cell numbers. This finding is at odds with that of the initial experiment 
which found that the lOOnM treatment was associated with a significant increase in 
cell numbers. This discrepancy may be due to an inter-donor variation caused by 
differences in age (69:31) or sex (F:?).although this concept is not supported by 
recent findings suggesting that the proliferative potential of BMSC declines with age 
and that gender has no effect^^7
Examination of the number of cells in the control cultures of both experiments reveals 
no significant difference1 suggesting donor age is not a major influence on cell 
proliferation in this case. It is possible that an age related response to PTH could be 
responsible for the difference. However, this is not supported by the findings of the 
work of Dr Sue Walsh1 who found no age-related correlation with cAMP response. 
Evidence from a rat m arrow 298 an(j human trabecular explant m odel299 suggesting 
that PTH induced cAMP responses are reduced with age, only serves to confound the 
issue.
Where PTH was supplemented with Dx, a dose dependent increase in cell numbers 
was seen and this increase was significant in the lOOnM Dx treatments. This is
1 Unpublished results from this lab.
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similar to the effect seen in the comparable treatment groups in the initial PTH dose 
response experiment. The Control Dx and IOnM Dx treatments had fewer cells than 
the comparable -Dx cultures which is in accordance with the proliferative inhibition 
associated with Dx treatments *80 The lOOnM Dx treatment had more cells than the 
comparable -Dx and this may be due to synergy associated with the level of PTH 
applied.
When PTH was applied late, the number of cells in each of the treatment groups was 
lower than that of the comparable continuously treated and significantly so in the 
lOOnM groups.
This experiment does not provide evidence to support the concept that PTH, when 
present from the start of culture, increases the number of cells. However it does 
suggest that its late application has an inhibitory effect on cell numbers. This is 
supported by evidence that PTH exerts an inhibitory effect on osteogenic cells that is 
positively related to the differentiation stage294 p t h  stimulation of proliferation in 
cultured mouse calvaria reverts to inhibition when the cells reach an osteoblastic 
phenotype 144 p t h  has also been shown to increase proliferation in cells associated 
with trabecular bone, and when these cells were isolated and grown in vitro, after 12 
hours the effect of PTH had become in h ib ito ry ^ O O
The late application of PTH Dx caused a significant reduction in the number of cells 
in both the IOnM Dx and lOOnM Dx cultures. This supports the idea that the 
increases in cell numbers which are associated with the continuous application of 
PTH Dx are due to an influence on early events. Furthermore this finding provides 
further evidence that PTH inhibits cell proliferation in later stages of culture.
The effects of PTH on bone cell numbers can be summarised in the form of a simple 
model. PTH recruits cells from the non-adherent/uncommitted population and 
promotes them to adherent, committed cell types. This initially increases the number 
of cells in the system. These cells proliferate and proceed along the differentiation 
pathway and, with increasing differentiation the inhibitory influence of PTH is also 
increased. When PTH is applied early, the recruitment of non-adherent/uncommitted 
cells goes some way to compensate for the inhibitory effects of PTH and, dependent 
on how long the cells spend in culture, can result in an increase in numbers. The late 
application of PTH does not provide the opportunity to recruit additional cells so the 
main effect is inhibitory and results in a reduction in cell numbers.
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Treatment with hPTH at IOnM and lOOnM significantly increased the numbers of 
colonies compared to the control. This is similar to the findings of the PTH dose 
response experiment, where the IOnM treatment was also significantly higher than the 
control while the lOOnM although higher, was not significantly so. The present 
experiment also yielded more colonies for a given treatment group than the initial 
dose response experiment, this may be a result of inter-donor sex/age differences 
although the findings of recent research does not support this concept^^.
Treatment with PTH Dx was associated with a significant reduction in the number of 
colonies in the IOnM Dx cultures and a small insignificant rise in the lOOnM Dx 
group. This compares to the previous experiment where a small increase was seen in 
the IOnM Dx cultures and a larger significant rise in the lOOnM Dx.
Late treatments with PTH caused a significant reduction in the number of colonies 
compared to the control. This was also true in PTH Dx groups. Comparing the late 
treatments with the continuous reveals a reduction in the number of colonies in all the 
late treated groups. This deficit was significant in the lOOnM, IOnM Dx and the 
lOOnM Dx treatments.
These findings are in accordance with the idea that treatment with PTH enhances the 
recruitment of a non-adherent/uncommitted population and that PTH must be present 
early to achieve this. These results also suggest that the presence of PTH in later 
stages of culture have an inhibitory effect on the development of colonies. This effect 
is unlikely to be due to an inhibition of initial adherence/recruitment of cells as PTH 
is not present at that stage. The influence could be mediated via an inhibition of 
proliferation i.e. when a proportion of adherent cells with the potential to develop into 
colonies are inhibited or arrested in growth by the presence of PTH.
An indication as to the proliferative potential of a colony is provided by the colony 
area 180 an(j density. In the late treated PTH cultures the dose dependent reduction in 
mean colony area, although statistically insignificant, support the hypothesis that the 
late application of PTH inhibits colony proliferation. The same effect is not seen 
when Dx is added to the system, this could be because the inhibitory effect Dx has on 
colony proliferation 180 masks the effects of the PTH.
As the total colony area of a culture is a function of mean colony size and number, 
the total colony areas in the cultures where PTH±Dx is added late are markedly 
reduced in a dose dependant manner.
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Treatment with PTH±Dx caused a significant increase in the number of AP+ colonies 
in a manner similar to that seen in the initial PTH dose response experiment. As in the 
previous experiment this increase is mainly, but not entirely, due to the presence of a 
greater number of colonies in these groups. The level of correlation between these 
parameters suggests that, to a lesser extent, other influences are involved in this 
increase. It is therefore possible that PTH treatment also enhances osteogenic 
differentiation.
In cultures where PTH±Dx was applied late, the number of AP+ colonies were equal 
to or significantly less than the controls. This decrease in AP+ colonies is primarily 
related to the number of colonies in cultures although to a lesser extent, other 
influences such as inhibition of osteogenic differentiation might be involved. The 
proliferative potential of AP+ colonies is inhibited by the late application of PTH as 
evidenced by the reduction in mean colony area. This deficit acts in concert with the 
reduced number of AP+ colonies in these cultures to bring about the marked dose 
dependant reduction in total AP+ colony area.
Although the correlation between the total number of colonies and the number of 
AP+ colonies suggests that the latter is primarily a function of the former, the 
coefficient value suggested that other lesser influences were also involved. Analysis 
of the cell surface expression of the STRO-1 and AP antigens reveals that treatment 
with PTH is associated with a small increase in the percentage of STRO-1 -/AP+ cells. 
When Dx is present in this system the proportion of these differentiated cells is 
increased. Late treatment with PTH reverses these effects. This suggests that early 
PTH treatment is enhancing osteogenic differentiation as evidenced by increased 
proportions of STRO-1 -/AP+ cells and it is likely that the increase in AP+ colonies is 
partly due to this effect. It also provides evidence that the late administration of PTH 
inhibits osteogenic differentiation and contributes to the reduction of AP+ colonies 
seen in these groups.
Previously discussed w o rk294 ,296  argues against PTH having a direct osteogenic 
influence on cells in the later stages of the osteoblast lineage. It may be that PTH 
recruitment of non-adherent/committed cells preferentially favours cells with greater 
osteogenic potential, thereby increasing their proportions in culture. Either way, the 
evidence provided by this experiment, and that of work already discussed, is not 
sufficient to define a mechanism whereby cultures exposed early to PTH have 
increased numbers of AP+ colonies and STRO-1-/AP+ cells.
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6.5: Summary.
Comparison of the results from controls, continuous and late treatments give support 
to the notion that PTH is required early in culture to bring about positive osteogenic 
changes. This is evidenced by increased numbers of AP+ colonies and proportions of 
STRO-1-/AP+ cells in the continuous treatments. The reduction in these parameters 
and in virtually all those measured in the late treated groups provides additional 
evidence suggesting that late treatment with PTH has an inhibitory effect on 
osteogenic differentiation in this system. This finding encourages an investigation 
into the effects of early PTH treatments on BMSC.
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Chapter 7: The I n  V i tr o  Effects Of Early Parathyroid Hormone 
Treatments On Bone Marrow Stromal Cells.
182
7.1: Introduction.
The initial PTH dose response experiment demonstrated that continuous treatment 
with PTH at concentrations of IOnM and lOOnM is capable of increasing the number 
of colonies, cells and when applied with Dx, AP+ colonies in cultures of human 
BMSC. This suggests that PTH targets early (uncommitted) cells and affects their 
adhesion and/or the recruitment to their osteogenic lineage. The subsequent 
experiment in which PTH treatments were applied late reaffirmed this possibility and 
provided additional information that suggested late treatment with PTH is associated 
with an inhibition of osteogenic differentiation.
On the basis of these findings it was postulated that the positive effects of PTH on 
osteogenic differentiation depend on the hormone being present at the earliest stages 
of culture and that its presence at later stages is associated with an inhibition of this 
process. To test this hypothesis, experiments were performed in which PTH was 
applied from the start of the culture period (continuous) and also applied to the 
culture for the initial 48 hours only (early). The rationale for this regime is, in the 
early system, the suggested positive effects of PTH treatment on the recruitment of 
non-adherent/uncommitted cells will not be attenuated by the negative effects 
associated with its presence late in culture.
7.2: Methods.
Bone marrow cells were obtained as described previously, from segments of rib 
removed from a male patient aged 66, during routine thoracic surgery at Frenchay 
Hospital, Bristol. Cells were plated at a density of 2 x 105/cm2 and cultured for 21 
days in standard media formulation supplemented with IOOjiM ascorbate-2-phosphate 
with or without hPTH(l-34) at IOnM and lOOnM and in the presence or absence of 
Dx.
The following parameters were assessed using cells seeded into T75 flasks 
(X4/treatment), cell numbers, surface expression of STRO-1 and AP and the 
expression of mRNA transcripts for OC, BSP CBFA1 and GAPDH. To estimate the 
effects on colony forming efficiency (CFE), and colony area, cells were seeded in 
petri dishes (4 petris/treatment).
To investigate the interaction between PTH and Dx, bone marrow cells were obtained 
as described previously, from segments of rib removed from 3 patients (2 male, 1 
female) age range 52-73 (mean 65 during routine thoracic surgery at Frenchay
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Hospital, Bristol. Cells were plated at a density of 2 x 105/cm2 and cultured for 21 
days in standard media formulation supplemented with lOOpM ascorbate-2-phosphate 
with or without hPTH(l-34) at IOnM and in the presence and absence of Dx.
To assess the effects of Dx on the expression of the PTH receptor (PTHrl) by flow 
cytom etry, cells were seeded (2 x 105/cm2) in T75 culture flasks 
(x4/treatment/analysis) and cultured for 21 days. For the measurement of intracellular 
cAMP levels, cells were plated in 6 well plates overnight (xl plate/treatment).
For both experiments, cells were cultured at 37 °C in a humidified atmosphere of 95% 
air/5 % CO 2. After 48 hours, the non-adherent cells were removed, the cultures were 
replenished with appropriate medium and fed twice weekly thereafter. At the 
appropriate time point, the cells were harvested and parameters assessed according to 
methods described in Chapter 2.
All experiments were repeated at least once and data from a single representative 
experiment is shown. The distribution of the data was confirmed as normal using the 
Shapiro Wilk W test, where data was not normally distributed, a log transformation 
was used to normalise the distribution prior to test. Differences in the data were 
assessed using the one way Analysis of Variance followed by the Tukey-Kramer test 
of Honest Significant Difference (p < 0.05).
7.3: Results.
7.3.1: Cell Morphology.
The continuous presence of PTH affected the morphology of the cells in a similar 
manner to that seen in the previous experiments. These changes were also apparent in 
cultures where PTH was applied early. Dx produced changes which were similar to 
those seen in the previous experiments.
7.3.2: Cell Numbers.
In the absence of Dx, continuous treatment with PTH did not effect cell number (fig. 
7.1a). In the presence of Dx, treatment with PTH was associated with a dose 
dependent increase in cell number, p < 0.05 at lOOnM. When PTH was applied early, 
a small insignificant dose dependent increase in numbers was seen (fig. 7.1b). In the 
PTH+Dx groups a similar increase was noted and this was significant in the lOOnM 
Dx cultures. Comparing the continuous and early treatments revealed no significant 
differences in cell numbers
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7.3.3: Total Number of Colonies.
Continuous treatment with PTH increased the number of colonies in a dose dependent 
manner although this increase was not significant (figs. 7.2a; 7.3a). In cultures treated 
with PTH+Dx a significant increase (p < 0.05) in the number of colonies was seen in 
the lOOnM Dx group (figs. 7.2b; 7.3a). When PTH was applied early, the number 
colonies was significantly increased (p < 0.05) in a dose dependent manner (figs. 
7.2c; 7.3b). This was also true of cultures treated with PTH+Dx (figs. 7.2d; 7.3b).
7.3.4: Mean Colony Area.
Continuous treatment with PTH±Dx did not significantly effect on the mean area of 
the colonies (fig. 7.4a). In the early treatments, where Dx was added, a dose 
dependent increase in mean colony area was significant in the lOOnM Dx cultures 
(fig. 7.4b).
7.3.5: Total Colony Area.
Continuous PTH treatment was associated with increases in the total colony area (fig. 
7.5a). In PTH+Dx treated cultures these increases were dose dependent and in the 
lOOnM Dx group, substantial (>100%). Early PTH treatment was associated with 
increases in the total colony area (fig. 7.5b). In PTH+Dx treated cultures these 
increases were dose dependent and in the lOOnM Dx group, substantial (>500%). The 
total areas in the early PTH+Dx treated cultures was greater than those of the 
continuously treated.
7.3.6: AP+ Colonies.
Irrespective of the presence or absence of Dx, treatment with PTH whether 
continuous or early resulted in a significant increase (p < 0.05) in the number of AP+ 
colonies that formed (figs. 7.6a-d; 7.7a,b). Independently of the presence or absence 
of Dx, the total number of colonies formed in the cultures treated early with PTH was 
significantly greater than that of cultures treated with the hormone continuously.
7.3.7: AP+ Colony Mean Area.
AP+ colony area was not affected by any treatment (figs. 7.8a,b).
7.3.8: AP+ Colony Total Area.
Continuous PTH treatments were associated with increases in total colony areas (fig. 
7.9a). In PTH+Dx treated cultures these increases were dose dependent and at 
lOOnM, substantial (>200%). Early PTH treatment was associated with increases in 
the total colony area (fig. 7.9b). In PTH+Dx treated cultures a similar increase was 
seen in the lOOnM Dx group while an increase in the IOnM Dx was considerable.
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7.3.9: Percentage of Colonies Expressing AP.
Early but not continuous, treatment with PTH was associated with a significant 
increase (p < 0.05) in the proportions of AP+ colonies that formed (fig. 7.10a,b). This 
was the case whether with or without Dx.
7.3.10: Flow Cvtometrv.
Continuous treatment with PTH was associated with increased proportions of cells in 
the STRO-1-/AP+ population (figs. 7.11b-d; 7.15a). PTH+Dx treatment increased the 
proportions of cells in the STRO-1-/AP+ population and reduced the proportions of 
STRO-1-/AP- cells (figs. 7.12b-d; 7.15b).
Early PTH treatment with lOOnM increased the proportions of cells in the STRO-1- 
/AP+ sub-population and reduced the proportions in the STRO-1-/AP- group (figs. 
7.13b,d; 7.16a). lOOnM PTH+Dx considerably increased the percentage of cells in the 
STRO-1-/AP+ population and reduced the proportion of cells in the STRO-1-/AP- 
group (figs. 7.14b,d; 7.16b).
7.3.11: Expression of OC. BSP. CBFA1.
The expression of mRNA transcripts for OC, BSP and CBFA1 was detected under all 
conditions of culture. In the absence of Dx, treatment with PTH whether early or 
continuous did not effect their steady state level of expression (not shown). In the 
presence of Dx however, (fig. 7.17) steady state levels of expression were greater, 
and treatment with PTH was associated with an increase in the steady state level of 
BSP transcript, which was considerably greater in cultures exposed to the hormone 
for the first 48 hrs only. Treatment with PTH whether early or late was associated 
with a marked up-regulation in the steady state level of transcripts for CBFA1.
7.3.12: PTHr Expression and Intracellular cAMP Levels.
Treatment with Dx consistently increased the percentage of cells expressing the PTHr 
and increased cAMP response to PTH treatment (Table 7.1).
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Figure 7.1 : Effect of PTH±Dx Treatment on Cell Number,
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Figure 7.2: Photographs showing colony coverage at 21 days
in response to continuous treatment with (a) PTH; (b) PTH Dx. 
and early treatment with (c) PTH; (d) PTH Dx.
Figure 7.2: Effect of PTH±Dx Treatment on Colony Number,















Figure 7.2: Photographs showing colony coverage at 21 days
in response to continuous treatment with (a) PTH; (b) PTH Dx. 
and early treatment with (c) PTH; (d) FTH Dx.
Figure 7.2: Effect of PTH±Dx Treatment on Colony Number.
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Figure 7.4: Effect of PTH±Dx Treatment on Mean Colony Area,
(a) Continuous and (b) Early.
Error bars represent S.E. of mean; n = 4 

















































Figure 7.5: Effect of PTH±Dx Treatment on Total Colony Area,





















































Figure 7.6: Photographs showing AP+ colony coverage at 21 days
in response to continuous treatment with (a) PTH; (b) PTH Dx. 
and early treatment with (c) PTH; (d) PTH Dx.
Figure 7.6: Effect of PTH±Dx Treatment on AP+ Colony Number,
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Figure 7.8: Effect of PTH±Dx Treatment on AP+ Mean Colony Area.



























































Figure 7.9: Effect of PTH±Dx Treatment on AP+ Total Colony Area.
(a) Continuous and (b) Early.
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Figure: 7.10: Effect of PTH±Dx Treatment on Percentage of Colonies
















Error bars represent S.E. of mean; n = 4; 









































































Figure 7.11 (a-d): Effect of Continuous PTH Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the x  -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 7.12 (a-d): Effect of Continuous PTH Dx Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the x  -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 7.13 (a-d): Effect of Early PTH Treatment on the Co-Expression
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 










Figure 7.14 (a-d): Effect of Early PTH Dx Treatment on the Co-Expression
of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
Isotype matched 
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Cells that had been dual-labelled for expression of STRO-1 and AP 
antigens were visualised as dot plots with green fluorescence (FITC) 
on the jc -axis and red fluorescence(R-PE) on the y—axis. Quadrants 
were set using the negative control sample such that >95% of cells 
appeared within the lower left quadrant (a).
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Figure 7.15: Effect of the Continuous Treatment with (a) PTH and (b) PTH Dx
on the Co-Expression of STRO-1 and AP Antigens as Assessed by Flow Cytometry.
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Relative proportions of sub-populations of cells labelled with the STRO-1 
and AP antibodies. Block areas represent relative sub-population sizes, 
numbers associated with blocks are percentage of cells (to nearest percent). 
Arrows represent the direction of increasing osteogenic differentiation.
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Figure 7.16: Effect of the Early Treatment with (a) PTH and (b) PTH Dx on the
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Relative proportions of sub-populations of cells labelled with the STRO-1 
and AP antibodies. Block areas represent relative sub-population sizes, 
numbers associated with blocks are percentage of cells (to nearest percent). 
Arrows represent the direction of increasing osteogenic differentiation.
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Figure 7.17: Expression of osteoblast related transcripts of BSP, OC, CBFA1. 
Figure shows Southern Blots of the RTPCR products probed with specific oligos 
recognising sequences internal to those used for the PCR.
Figure 7.17:Effect of Treatment with PTH on theExpression









Table 7.1: Effect of PTH on the Intracellular Accumulation of cAMP.
cAMP response to PTH 
% Cells and Dx treatment,-
PTHr +ve MFI % of non-stimulated control
Donor Sex Age -Dx +Dx -Dx +Dx +Dx +PTH +PTH+DX
1 F 73 32.3 49.6 16.4 16.3 81± 9.4 114± 2.8 U> ? 1—k s 00
2 M 70 43.6 58.1 12.9 12.5 126tl8.8 138tl6.1 621± 61.8
3 M 52 83.4 85.5 35.2 47.8 175±12.1 106tl5 738± 68.7
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7.4: Discussion.
Both continuous and early treatment with PTH caused changes in BMSC morphology 
similar to that seen in the previous experiments. Considering these observations along 
with the effects witnessed in the late treated cultures of the previous experiment 
suggests that PTH must be in the culture system early in order to affect cell 
morphology. The results of this experiment add weight to the suggestion that PTH 
targets less differentiated cells 296 while concomitantly inhibiting the differentiation 
and proliferation of more cells at later stages for differentiation 144,294,300
The effect of PTH treatments on cell numbers in the continuous treatments was 
similar to that seen in the previous experiment and where PTH was supplemented 
with Dx, the significant increase seen in the lOOnM Dx was in accordance with the 
previous findings. Consistent with the previous experiments, PTH treatment increased 
the number of colonies and this increase was also apparent when Dx was added to the 
system. When PTH±Dx was added early, the increases in colony numbers was greater 
than that seen in the continuously treated. This increase might be explained by the 
model discussed previously, (i) The presence of PTH at initiation of cultures recruits 
un-committed/non-adherent cells and promotes them to adherent/committed types, 
(ii) The presence of PTH in the post adherence stage acts to inhibit the proliferation 
and differentiation of these recruits and other adherent cells. An analysis of the mean 
colony areas, an indicator of colony proliferation 180, supports this thesis, in cultures 
where PTH was applied (and removed) early the mean colony area was greater than 
that of the comparable continuous treatments.
Consistent with the previous experiment, treatment with PTH+DX caused a 
significant increase in the number of AP+ colonies. When treatment was applied early 
this increase was significantly greater. Expressing this increase as a percentage of the 
total colonies reveals significantly higher values in the early treatments. This increase 
in AP+ seen in the early treatments might be explained if PTH preferentially recruited 
a sub-population of non-adherent/uncommitted cells which had a greater osteogenic 
potential. It might also be explained by a PTH induced increase in osteogenic 
differentiation although previous studies in this area suggest that this is not the 
case 144,294,300 Early treatment with PTH±Dx at lOOnM produced meaningful 
changes in the STRO-1/AP sub-populations which was suggestive of an increase in 
osteogenic differentiation. If it is accepted that PTH does not directly increase 
osteogenic differentiation per se then this effect might be explained by a PTH 
induced increase in the proportions of cells of the osteogenic phenotype.
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Analysis of mRNA transcripts for osteocalcin (O C) bone sialoprotein (B SP), late 
stage markers of osteogenic d iffe re n tia tio n  1 2 ,3 0  1 ,3 0 2  an(j C B F A 1/O S F 2 , a 
transcription factor essential for osteogenic differentiation^^-0-212 reyeals inter­
treatment differences in mRNA levels for B SP and CBFA1 when Dx is present in the 
system. OC levels appeared to be unaffected by treatments, PTH  has previously been 
shown to both inhibit O C production303,304 and increase OC gene expression 305 so 
the finding of this study adds little to that debate. Treatment with PT H  Dx both 
continuously and early, caused similar increases in levels of B S P  mRNA, this 
increase is consistent with previous work on PTH  effec ts^a lth o u g h  it is not clear 
whether this upregulation is caused by an increase in osteogenic differentiation or, if 
PT H  simply causes an increase in levels of this protein.
mRNA for the transcription factor CBFA1 was upregulated by continuous treatment 
at lOOnM Dx and by early treatment of PTH Dx. In osteogenesis, CBFA1 is a crucial 
transcription factor that induces osteoblast related genes209 an(j has the ability to up- 
regulate these genes in pre-osteoblastic or non-osteoblastic c e l l s  210. The upregulation 
of CBFA1 by PTH provides a mechanism by which PTH might recruit non­
adherent/uncommitted cells to the osteogenic lineage and thereby increase the 
proportions of osteogenic cells in culture.
The interaction between PTH and Dx seen in this and other studies 3 0 7 - 3 1 0  c a n  he 
partly explained by Table 7 . 1 .  This table shows the effects of Dx on PTHr expression 
and the associated cAMP response in BMSC from three donors. The addition of Dx 
consistently increased the proportion of cells expressing PTHr and concomitantly 
increased the cAMP response when Dx was applied with PTH. This finding is in 
accordance with the suggestion that Dx increases the proportions of cells expressing 
PTHr by increasing the transcription rate of the PTHr g e n e 3 0 8  The level of 
expression of PTHr per cell is indicated by the Mean Fluorescent Intensity (MFI) and 
in these samples this parameter does not seem to play a major part in the increase in 
cAMP response associated with the combination treatment. Dx might also potentiate 
hormone responsiveness through promotion of hormone-receptor-adenyl cyclase 
coupling 310 although the evidence derived from this experiment is not sufficient to 
allow comment on this possibility.
7.5: Summary.
The findings of the PTH study allows the definition of a simple model system: 
Treatment with PTH at the initiation of culture promotes uncommitted/non-adherent 
cells to a more committed phenotype via PTH induced upregulation of CBFA1 gene
206
expression and thereby increases the pool of osteoprogenitors. The addition of Dx to 
the system enhances this effect by upregulating the proportions of cells expressing the 
PTHrl receptor and potentiating the hormone-receptor-adenyl cyclase coupling 310. 
Subsequent proliferation and differentiation of the adherent cells is inhibited by the 
presence of PTH, the level of inhibition increasing with differen tia tion294,311,312 
The different actions of PTH which are seen at different levels of maturation could be 
due to the increasing expression of PTHr associated with increasing 
differentiation 279,313
This model could be developed in a number of ways, optimisation of the duration of 
the early PTH treatment may reveal greater osteogenic effects. It is possible that an 
investigation of the correlation between PTHr expression and differentiation would 
provide clues as to the cause of the disparate effects seen with PTH treatments. 
Additionally, a knowledge of the relative contributions of the PKA/PKC signalling 
pathways to the differing effects could prove to be useful.
It is widely accepted that the intermittent application of PTH modulates anabolic 
effects which are dependent on the time and duration of trea tm en ts314 ,315  The 
simple model system defined in this study provides one possible explanation as to 
how intermittent treatments could give rise to an increased pool of osteoprogenitors 
thereby enhancing anabolic potential. Development of this system could provide a 
basis to explore the disparate effects evident between treatment regimes and may lead 
to an understanding of the underlying cellular and molecular events. Understanding 





Osteoporosis is a significant cause of morbidity and mortality in the United Kingdom. 
As a focus of research, a wide range of strategies have been implemented in an 
attempt to elucidate the mechanisms underlying this problem. Human studies and 
research using in vivo animal models have been complemented by in vitro molecular 
and cell biology techniques.
Stem cell recruitment and promotion are important modulators of bone formation and 
a defect in this system has been suggested as a contributory factor in the pathogenesis 
of this condition. The realisation that these cells can be modulated by growth factors 
and hormones at the earliest stages of development gives rise to hope of therapies 
based on this type of manipulation. To date, the understanding of osteoblast 
recruitment and differentiation is incomplete and this deficit in knowledge hinders the 
development of such therapies.
This study set out to examine the potential of modulating osteoblast differentiation 
using growth factors and hormones and to ascertain if the temporal application and 
combination of these agents could be used to further enhance osteoblast progression.
In this study samples were rejected if patients had evidence of conditions (e.g. 
carcinoma) or therapies (e.g. glucocorticoids) known to affect bone metabolism. 
Despite this exclusion criteria inter-sample variability was occasionally seen between 
patients who were age and sex matched. These differences might be attributed to 
factors outside our control e.g. inconsistencies in handling samples and differences in 
transit times, but it is equally likely that as yet unknown biological mechanisms are 
involved.
This study has shown;
• Choice of serum supplement has important effects on the proliferation and 
differentiation of bone marrow stromal cells.
• When applied early to BMSC, FGF is a mitogen and positively influenced 
osteogenic differentiation. Early treatment with FGF selectively increased the 
proportion of cells present in the multipotential precursor and committed 
osteoprogenitor populations.
• Treatment with PTH promoted osteogenic differentiation, possibly by promoting 
uncommitted stem cells to the osteogenic lineage. This enhancement was
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increased when PTH was applied early and decreased when applied late. A 
positive osteogenic interaction between PTH and Dx was associated with a Dx 
related increase in the proportion of cells expressing PTHrl.
This study therefore, provides evidence that the manipulation of osteoblast 
differentiation at the stem cell level can be further enhanced by the temporal 
application of the growth factors, TGF-p and FGF-1 and the hormone, PTH. It is 
hoped that these findings may contribute to the understanding of bone stem cell 
recruitment and promotion, a process which is of fundamental importance to bone 
formation.
This type of study is limited in a number of ways. Samples of human marrow were 
obtained remotely from patients undergoing elective surgery and because of time 
constraints placed on surgical teams, it was not always possible to obtain full records 
of patient details. Often, only the minimum details of age, sex, disease status and 
current drug therapy were supplied. Ideally, the provision of a full medical history 
would allow the identification of previous conditions and this could add another 
dimension to the overall analysis.
8.2: Future Work.
In Vitro
• Further insights could be gained by expanding the temporal range of applications 
of these agents. A comparison of integrin expression and activation between 
treatment groups may provide clues to underlying mechanisms governing the 
promotion of non-adherent to adherent cells.
In Vivo
• These treatments, when applied in a suitable animal model, would allow the 
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Appendix.
Table 1: Age and Gender Details of Patients used in this Study.
Chapter________________________Sex_____________ Age
3: Testing of Serum Supplements Male 59
3: Testing of Serum Supplements Female 68
3: Testing of Serum Supplements Female 68
4: Effects of TGFp-1 and FGF-2 Treatment Female 68
5: Effect of PTH Treatment Female 68
6: Effect of Delayed PTH Treatment Unknown 31
7: Effect of Early PTH Treatment Male 66
7: Effect of Early PTH Treatment Male 52
7: Effect of Early PTH Treatment Male 73
7: Effect of Early PTH Treatment Female 65
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